



2014

PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN NSCLC

Christopher W. Stamatkin
University of Kentucky, stamatkin@gmail.com

[Click here to let us know how access to this document benefits you.](#)

Recommended Citation

Stamatkin, Christopher W., "PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN NSCLC" (2014). *Theses and Dissertations--Pharmacy*. 58.
https://uknowledge.uky.edu/pharmacy_etds/58

This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File.

I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

REVIEW, APPROVAL AND ACCEPTANCE

The document mentioned above has been reviewed and accepted by the student's advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student's thesis including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Christopher W. Stamatkin, Student

Ester P. Black Ph.D., Major Professor

Jim Pauly Ph.D., Director of Graduate Studies

PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN
NSCLC

DISSERTATION

A thesis in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in the College of Pharmacy at the University of Kentucky

By

Christopher Wayne Stamatkin

Lexington, Kentucky

Director: Ester P. Black Ph.D.

Lexington, Kentucky

2014

Copyright © Chris W. Stamatkin 2014

To my family,

You have been, and always shall be my strength. We now can exhale, smile,
and look forward to living. I love you. CS

TABLE OF CONTENTS

ACKNOWLEDGMENTS	iii
LIST OF TABLES	vi
LIST OF FIGURES	vii
CHAPTER 1: INTRODUCTION	1
1.1. LUNG CANCER OVERVIEW.....	1
1.2. THE BIOLOGY OF PI3K.....	11
1.3. ACTIVATION OF PI3K/AKT PATHWAY IN LUNG CANCER	22
1.4. PROJECT OVERVIEW.....	33
CHAPTER 2:	35
2.1. OVERVIEW	35
2.2. METHODS.....	37
2.3. RESULTS	42
2.4. DISCUSSION.....	63
2.5. CONCLUSIONS.....	68
CHAPTER 3:	70
3.1. OVERVIEW	70
3.2. METHODS.....	74
3.3. RESULTS	76
3.4. DISCUSSION.....	83
3.5. CONCLUSIONS.....	87
CHAPTER 4:	88
4.1. SUMMARY OF RESULTS	88

4.2. CONTRIBUTION TO THE FIELD	89
4.3. TRANSLATIONAL AND CLINICAL RELEVANCE	91
4.4. CONCLUSIONS.....	94
APPENDIX:	96
APPENDIX I: Supplementary Figures for Chapter 2.....	96
REFERENCES	97
VITA.....	112

FIGURES AND TABLES:

LIST OF TABLES:

Table 2.1.	PI3K inhibitor IC ₅₀ selectivity profile	47
Table 2.2.	GI ₅₀ values of PI3K inhibitors for NSCLC cell lines52	48
Table 2.3.	Measurement of cell proliferation in synchronized NSCLC cell lines after PI3K inhibitor treatment	96
Table 3.1.	Summary of drug combinations with corresponding combination indices.....	82

LIST OF FIGURES:

Figure 1.1.	Domain structures and regulatory interactions of class IA PI3Ks..	15
Figure 1.2.	Canonical class IA PI3K activation.....	28
Figure 1.3.	Chemical structures of pan-class I and isoform-selective PI3K inhibitors.....	29
Figure 2.1.	Expression of class IA PI3K p110 isoforms and PTEN among NSCLC cell lines	45
Figure 2.2.	Class IA PI3K isoform activity ELISA.	46
Figure 2.3.	Growth inhibition activity PI3K inhibitors against a panel of 5 NSCLC cell lines	49
Figure 2.4.	Pharmacodynamic responses to PI3K isoform-selective inhibition	50
Figure 2.5.	Pharmacodynamic responses to pan-class I PI3K inhibitor ZSTK474.....	54
Figure 2.6.	Basal class IA PI3K expression, proliferation, and pharmacodynamics responses to isoform-selective inhibitors in PTEN-null prostate cancer cell line PC3	55
Figure 2.7.	Isoform-selective PI3K inhibitor treatment demonstrates time-dependent inhibition of PI3K signaling	56
Figure 2.8.	siRNA-mediated ablation of p110 β does not phenocopy effects observed with PIK3CB and D inhibition in NSCLC.....	59
Figure 2.9.	IC488743 and ZSTK474 treatment alters G ₁ cell cycle progression without inducing apoptosis	62

Figure 3.1.	Growth inhibition in KRAS mutant NSCLC induced by EGFR-TKI, erlotinib (ERL), and the pan-PI3K inhibitor, ZSTK474, alone and in combination.....	79
Figure 3.2.	Interaction of EGFR-TKI and pan-PI3K inhibitors in KRAS mutant NSCLC	80
Figure 3.3.	Proliferative responses and inhibitor interactions to combination EGFR-TKI and pan-PI3K inhibition in EGFR mutant, PTEN-null NSCLC.....	81

Chapter 1

1.1.1 Lung Cancer Overview

The genesis of the word cancer can be attributed to the Greek physician Hippocrates (460 - 370 B.C.), who is regarded as the “Father of Medicine.” His detailed study used the terms *karkinos* and *karkinoma* to distinguish non-ulcer forming and ulcer forming tumors [1]. The Greek definition of *karkinos* is crab, which among many other explanations is thought to describe the outward projections from a cancer akin to that resembling the shape of a crab. Centuries later, the Greek word was translated into Latin by the roman physician, Celsus (28 - 50 B.C.) giving us the modern word *cancer* [2].

Advancing twenty-two centuries, we now define cancer as the transformative biological response of a cell to both genetic and epigenetic changes shaped by environmental cues that together lead to uncontrolled cell proliferation and survival. This is a disease fundamentally occurring at the cellular level, and when compared to normal cells differ in a number of ways: control of growth, morphology, cell-cell interaction, membrane and cytoskeletal composition, protein synthesis, and gene expression [3].

At the causative core of these differences are two broad classes of genes that play an elementary role in the transformative progression to cancer called proto-oncogenes and tumor-suppressor genes. Oncogenes can be generally defined as any gene product capable of transforming cells. Proto-oncogenes play an evolutionarily conserved role in normal signaling networks controlling cellular differentiation, growth, survival and maintenance of tissues. Activation of

a proto-oncogene into an oncogene occurs through gain-of-function mutations that now express an oncoprotein capable of driving transformation process. Conversely, tumor-suppressor genes normally encode proteins that through various mechanisms act to limit cell proliferation [4]. These include proteins responsible for cell cycle control, and DNA repair, as well as critical mediators of apoptosis, among others. It is important to note that tumor-suppressor genes are recessive with regard to activity, meaning both copies of tumor-suppressor gene must be lost or inactivated to drive tumor progression. Familial inheritance of single copy mutant alleles for tumor suppressors, such as RB, APC, and BRCA1, dramatically increases the probability of a select tumor initiation [5]. Progression of cancers is highly variable and is dependent on a number of factors: namely the particular molecular drivers of disease, tissue of origin, immune system function, and micro-environmental cues [6].

As with other cancers, current treatment options for lung cancer are largely based upon stage of cancer upon diagnosis, however other factors such as overall health and lung function are important. For early stage (stage I/II) disease non-small cell lung cancer (NSCLC) patients are most likely to undergo surgery alone or in conjunction with adjuvant chemotherapy [7]. Patients with stage III diagnosis represent a heterogeneous group and treatment options are limited to the location of the tumor and whether surgery is possible. Patients may present disease ranging from resectable tumors with microscopic lymph node metastasis to large tumors involving multiple lymph nodes. Stage III NSCLC is addressed similar to early disease, albeit in a more aggressive manner with

increased use of radiotherapy or adjuvant chemotherapy. For newly diagnosed NSCLC, 40% of patients are found to have stage IV disease [8]. Treatment goals and options for stage IV NSCLC are no longer curative but rather to prolong survival and control cancer related symptoms. The first-line therapy for patients with advanced NSCLC are cytotoxic combination chemotherapy using a platinum based doublet (cisplatin or carboplatin) in tandem with a cytotoxic agents such as paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan and pemetrexed [9, 10]. More recent clinical studies also indicate potential benefit of adding molecularly targeted inhibitors, bevacizumab or cetuximab, to the cytotoxic combination chemotherapy [11]. For patients having identified EGFR mutations, the use of EGFR tyrosine kinase inhibitors (TKIs) are indicated as a first-line treatment, in addition to second- or third-line treatment for advanced NSCLC [12, 13]. In this era of molecular therapeutics, the discovery of clinically responsive EGFR mutations found in a small subset of lung adenocarcinomas and the promise of EGFR targeted therapeutics stands as model for future personalized care for advanced stage cancers. We now realize the clinical practice is gradually shifting from therapy based on clinicopathologic features to implementation of biomarker driven treatments based on a molecular profile of a patient's tumor.

1.1.2 Lung cancer etiology and epidemiology

Exactly 50 years ago the landmark publication "Smoking and Health: Report of the Advisory Committee to the U.S. Surgeon General of the Public

Health Service” concluded that cigarette smoking is a cause of lung cancer in men and sufficient in scope to demand “remedial action” for the betterment of society [14]. The call to action outlined in the 1964 report was followed by increased public awareness and shift in attitudes to smoking related health risks. In subsequent years, further action to increase regulatory oversight of use, sales, and advertising of tobacco products. The current Surgeon General report now concludes that active cigarette smoking is a cause of 1.) nine types of cancer, 2.) cardiovascular disease, 3.) chronic obstructive pulmonary disease, 4.) acute respiratory illness, 5.) respiratory effects having adverse impact on lung growth and function, 6.) reproductive associated complications, as well as numerous other deleterious health effects [15, 16].

Lung cancer was once considered a rare disease, however the onset of mechanization and wide scale marketing at the end of the 19th century brought cigarette smoking to the mainstream leaving behind a lung cancer epidemic [17]. The worldwide burden of lung cancer attributable to smoking is 80% for males and greater than 50% for females [18]. Lung cancer is now the leading cause of cancer-related death both in the United States and globally, accounting for 228,190 new diagnosis and 150,480 deaths in the United States for 2013 alone. [19, 20]. According to a 2012 Centers for Disease Control (CDC) study the Commonwealth of Kentucky was ranked first among all states for having the most adult cigarette smokers [21]. As a matter of public health, it is incumbent on our federal, state, and local officials to engage in anti-smoking efforts at all levels, knowing the best way to prevent lung cancer is to not smoke.

Tobacco smoke is composed of greater than 60 known carcinogens, with nearly half of which having a strong association with the development of lung cancer [22]. Among these carcinogens the best studied are the damaging effects of polycyclic aromatic hydrocarbons and the tobacco-specific nitrosamine 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone, each of which introduce mutations via DNA adduct formation [23]. Chronic exposure to the carcinogens found in tobacco smoke eventuates mutations in critical genes such as p53 and K-RAS, which may serve as an initiating event or contribute to the progression of disease. Secondary causes of lung cancer are attributable to workplace agents such as asbestos, chromium, nickel, arsenic, and radon, as well as environmental factors such as second hand smoke and air pollution [24].

There are primarily two histologically distinct forms of lung cancer, non-small cell lung cancer (NSCLC) accounting for 85% and small cell lung cancer (SCLC) representing approximately 15% of all lung cancers [25]. The overwhelming majority of lung cancer patients with NSCLC (85%) or SCLC (98%) are current smokers [26]. NSCLCs are further divided into three major sub-types, squamous cell carcinoma (SCC), adenocarcinoma (ADC), and large cell carcinomas (LCC). Lung adenocarcinoma is most common histological subtype of lung cancer accounting for nearly 40% of all lung cancer [27].

1.1.3 Lung cancer genetics

Significant advances have been made in delineating the cellular and molecular mechanisms directing tumor initiation, maintenance, and progression

of lung cancer. Susceptibility and risk of lung cancer been shown to have strong correlation with hereditary genetic factors, this is underscored by the observation that only 10-20% of smokers develop lung cancer [28]. Epidemiological studies indicate a 2.5 fold increase in risk of developing lung cancer related to a family history of lung cancer [29]. These risks are associated with common inherited cancer syndromes such as germ-line inactivating mutations in tumor suppressor genes TP53 and RB among others [30, 31]. However, loss-of-function mutations in these genes are common to a variety of cancers, and to date no conclusive familial link specific to the development lung cancer has been identified.

Apart from the familial predisposition to the development of lung cancer, environmental factors such as tobacco smoke cause DNA lesions directly involved in tumor initiation and progression. Large scale genomic studies indicate a given lung tumor is comprised of a large number of somatic mutations that occur over time [32, 33]. Indeed, both histologically normal bronchial epithelial cells and pre-neoplastic cells express many of these genetic and epigenetic abnormalities, suggesting human lung cancers arise from normal epithelium through a multistep accumulation of successive genetic and epigenetic changes [34]. Among the most common, and best studied of these related to the pathogenesis of lung cancer are the tumor suppressor TP53, and the proto-oncogenes RAS and EGFR.

TP53 (encoding protein p53) is the most frequently mutated gene in human cancer. Wild-type p53 functions as a sensor that determines cell fate by orchestrating the cellular response (DNA repair or apoptosis) to cell stress and

DNA damage. As a transcription factor, activated p53 promotes the expression of cell cycle inhibitory proteins causing G₀/G₁ cell cycle arrest and the induction of apoptosis [35]. When p53 is compromised, no longer can cells detect DNA damage and appropriately dictate the cellular responses needed, thus increasing the likelihood for acquiring DNA lesions and increasing overall genomic instability. Mutations in TP53 are present in approximately 50% of NSCLC tumors and 90% of SCLC cancers [24]. Therefore, loss of p53 can be viewed as a critical step influencing the development of lung cancer.

Proto-oncogenes in lung cancer

The deregulated signaling pathways that result directly or indirectly from the variety genetic mutations involved in lung cancer are important targets for current and future cancer therapies. The oncogenic signaling molecules and related pathways involved are common among many human cancer types besides lung cancer such as KRAS, EGFR, PIK3CA, BRAF, HER2 and EML-4ALK [36].

As a cancer develops these deregulated growth signals often lead to “oncogenic addiction,” whereby the tumor becomes completely reliant on these signals for survival. Consequently, if these oncogenic signals are blocked (e.g. by targeted drugs) those addicted cancers will die, whereas those cells not dependent remain largely insensitive to the particular drug activity [37]. The concept of targeted inhibition of tumor specific oncoproteins has led to tremendous genome wide sequencing and simultaneous drug development

efforts, to both identify, and develop rational therapeutics. The remainder of this section will focus those driver oncogenes most common to lung cancers, EGFR and K-RAS, and their interaction with PI3K signaling pathway.

Oncogenic EGFR signaling in lung cancer

The epidermal growth factor receptor (EGFR/ERBB1/HER1) is an important member of the cell surface receptor super-family of receptor tyrosine kinases (RTKs) that are critical mediators of cell signaling by extracellular growth factors. In addition to EGFR, the other family members include ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4, each of which have garnered much attention provided their association with the development and progression of many human tumors [38]. The EGFR proto-oncogene plays an important role in normal cell proliferation, apoptosis, and angiogenesis, both the receptor and its ligands are frequently overexpressed in the development and maintenance of non-small cell lung cancer (NSCLC) [39, 40].

Over the past decade, the development of small molecule inhibitors of EGFR activity were developed as anti-cancer agents, these being erlotinib (OSI Pharmaceuticals) and gefitinib (AstraZeneca) [41, 42]. Subsequent studies indicated a subset of patients with chemo-refractory NSCLC demonstrated dramatic, though often not sustained response to inhibitors of EGFR [43]. Among those patients exhibiting tumor regressions, response was found to correlate with mutations of EGFR found in the kinase domain (exons 18-24) of the molecule [44, 45]. EGFR kinase domain mutations are restricted to only a

subset of NSCLC, comprising approximately 10-20% of NSCLC cases [46, 47]. Deletions in exon 19 (most often del746-750) and point mutations in exons 18 (G718A/C), 20 (T790M) and 21 (L585R) lead to the increased and sustained activation of the receptor [48]. Downstream of mutant EGFR are the PI3K/AKT, RAS/MAPK, and STAT pathways, which are regulated and dependent on the deregulated EGFR signaling [49]. Treatment with EGFR-TKIs in these “EGFR addicted” NSCLC tumors shuts down the growth and survival signaling through these pathways and cells undergo considerable apoptosis. However, significant initial tumor regressions are only temporary in response to EGFR-TKI treatments; these cancers inevitably become resistant to therapy within 12 months [50-52]. However, complicating this effort are the approximately 10-20% of patients who do demonstrate a partial response to EGFR-TKI, but do not have identifiable EGFR mutations, suggesting that other mechanisms and pathway activity apart from mutant EGFR underlie responsiveness [53, 54].

Such insights into EGFR-dependent signaling highlight the ongoing difficulty in identifying clinically suitable patient populations for EGFR-TKI therapy and the potential for rational combination therapies targeting other compensatory drivers of disease.

Mutant K-RAS signaling in lung cancer

Approximately 30% of human tumors harbor RAS gene mutations [55], this includes a high prevalence in lung cancers at approximately 25-50% [56, 57]. The RAS family of proto-oncogenes (H-RAS, K-RAS, and N-RAS) are membrane

associated small G proteins that regulate critical signaling responsible for normal cell proliferation, differentiation, and survival [58-60] . The RAS proteins functionally serve as a link between the upstream receptor tyrosine kinases (RTKs), and the downstream serine/threonine kinases of MAPK pathway [61, 62]. RAS also plays an important role upstream of PI3K signaling, acting as a positive regulator of PI3K activation [63]. GDP-bound RAS is inactive, however conversion to active state, GTP-bound RAS, is carried out by guanine nucleotide exchange factors (GEFs). GTPase-activating proteins (GAPs) return RAS to inactive state by hydrolyzing GTP into GDP.

Mutations affecting KRAS represent greater than 90% of RAS mutations found in NSCLC, most having single base pair mutations in codons 12 and to a lesser extent codon 13 which makeup the guanine binding domain of RAS [64]. Furthermore, lung adenocarcinomas having activating mutations in codons 12 and 13 of KRAS are almost entirely found in patients with a history of cigarette smoking [65, 66], whereas EGFR mutations are more common in never smokers [28, 33]. Mechanistically, these mutations lock the RAS protein into the active GTP-bound conformation that leads to persistent signaling downstream via PI3K/AKT/mTOR and RAF/MEK/ERK pathway effectors leading to sustained proliferative and pro-survival signaling. Attempts to develop targeted inhibitors of RAS have thus far been unsuccessful which has made treatment of RAS mutant cancers difficult. Current drug discovery efforts are now aimed downstream of activated RAS, as indicated by the clinical emergence of RAF and MEK kinase inhibitors [67-69].

1.2 THE BIOLOGY OF PI3K

Phosphoinositide-3-kinases (PI3Ks) form a family of lipid kinases that functionally generate intracellular phospholipid species that affect a wide range of biological activities. Specifically, activated PI3Ks phosphorylate the 3-OH group of membrane lipid phosphatidylinositol (4,5) biphosphate (PIP₂) to form phosphatidylinositol (3,4,5) triphosphate (PIP₃) that function as second messengers providing both specific spatial and temporal signals that modulate the activity of intracellular protein effectors responsible for a wide range of cellular functions [70-74] .

A large body of research has identified an evolutionarily conserved family of PI3K enzyme organized into 3 classes (Class I, Class II, and Class III) on the basis of structural characteristics, tissue distribution, regulation, and lipid substrate preference. The best characterized of these, Class I PI3Ks are composed of p110 α (PIK3CA), p110 β (PIK3CB), p110 γ (PIK3CG), and p110 δ (PIK3CD) [75-77]. Class II PI3Ks PI3K-C2 α (PIK3C2A), PI3K-C2 β (PIK3C2B), PI3K-C2 γ (PIK3C2G) remain elusive, having are poorly understood roles in cell signaling [78] . Finally, Class III PI3K is only comprised of VPS34 (PIK3C3), which initial studies report having a role in endosomal sorting of proteins [79]. The isoform specific functional activities of the class I PI3Ks and involvement in human cancers will largely be the focus of further discussion below.

1.2.1 Class I PI3Ks

Structural organization of p85:p110 heterodimers

The catalytic p110 subunits are further sub-divided into class IA composed of (p110 α , p110 β , p110 δ), each associating with the p85-type (p85 α or p85 β) of regulatory subunit, whereas class IB sub-group (p110 γ) binds either p101 or p87 regulatory subunits [80-82].

The class IA regulatory p85 α/β and catalytic p110 $\alpha/\beta/\delta$ are multi-domain proteins that functionally interact with upstream and downstream effectors (Figure 1.1.). The full length p85 isoforms, α or β , are composed of N-terminal Src homology 3 domain (SH3) then a breakpoint cluster region (BCR) homology domain flanked by proline rich domains, and three SH2 domains (nSH2, iSH2 and cSH2) [71]. The p110 catalytic subunit is composed of N-terminal adaptor binding domain (ABD), Ras binding domain (RBD), C2 core structure, helical domain and the kinase domain [83] (Figure 1.1.).

Activation of class IA PI3Ks is strictly regulated by the obligate regulatory subunits association with the catalytic subunit [84]. Importantly, the regulatory interactions of p85 that control enzymatic activity differ depending on the particular class IA p110 isotype to which it is associated. Regulation of p110 α and δ catalytic activity is mediated by two groups of inhibitory contacts: (I) SH2 (N-terminal SH2) domains of 85 α make contacts with the helical domain, C2, and the kinase domain; and (II) the iSH2 (inter- SH2) domain of p85 forming inhibitory contacts with the ABD and C2 domains of p110 α (Figure 1.1.; solid lines 1 & 2) [83]. The c-SH2 (C-terminal SH2) of p85 does not provide any inhibitory

involvement in for the p110 α isoform. However, for p110 β this is not true, in addition to the regulation by the nSH2 and iSH2 contacts, p110 β has an additional inhibitory contact between cSH2 domain of p85 and the kinase domain (Figure 1.1., dashed line 3). These differences in p85:p110 regulation unique to p110 α/δ and p110 β comprise functional molecules that have very different interaction and activation requirements among the PI3K isoforms which ultimately impart isoform specific function in cells [85-87].

Regulatory and catalytic mechanism of PI3Ks

A common feature of PI3K and other protein kinases are the shared bi-lobal structural organization of the kinase domains where ATP is bound between the lobes [88]. The N-terminal lobe of PI3Ks is composed of highly conserved five-stranded β -sheet and the regulatory element $\kappa\alpha 3$ helix oriented tightly along the helical and ABD domains [89]. The C-terminal lobe is composed of mostly α -helices that are oriented to allow for membrane interaction, receptivity of lipid substrates, and the p85 regulatory subunit [87]. A distinct structural element of the C-lobe are the $\kappa\alpha 10$, $\kappa\alpha 11$, and $\kappa\alpha 12$ helices which make up the regulatory arch that encloses the activation and catalytic loops required for catalysis [90]. Multiple conformations of $\kappa\alpha 12$ helices have been identified, which have been attributed to its central role in membrane binding and thus the overall activity of the kinase [91]. The helix is thought to maintain the closed-inactive conformation of the enzyme in absence of lipid membrane, thus limiting substrate access to the active site. The $\kappa\alpha 10$, $\kappa\alpha 11$, $\kappa\alpha 10$ helices of the regulatory arch are also

important because they interact with nSH2 and cSH2 of p85 as well as other regulatory proteins that modify the active conformation of catalytic loop [92]. The catalytic domains of PI3K are spatially oriented by the conserved hydrophobic domains called the regulatory (R-spine) and catalytic spine (C-spine). Together these build the scaffold for the catalytic loop and placement of ATP [90, 93]. Thus, in the presence of membrane lipid substrate, binding by the activation loop and helix $\alpha 12$ causes the conformation change needed fully accommodate the lipid substrate, and simultaneously relieves inactive conformation in the catalytic center to its fully active state [87] .




Figure 1.1. The domain structures and regulatory interactions of class IA PI3Ks. Illustration depicts the interaction of class IA PI3K heterodimers with various upstream signaling molecules known to activate PI3K. Solid Black and grey lines (1 & 2) represent common inhibitory contacts between p85 regulatory and p110 catalytic subunits. Dashed line (3) represents a unique third inhibitory contact found only in p85:p110 β interaction.

1.2.2 Canonical Class I PI3K activation

The canonical PI3K signaling pathway can be activated by RTKs (with or without adaptor molecules), RAS, or GPCRs (Figure 1.2.).

Activation by receptor tyrosine kinases

In quiescent cells, cytosolic PI3K p110 catalytic subunits are stabilized and sustained in the inactive state by p85 regulatory subunit interaction. Upon growth factor stimulation, receptor tyrosine kinases (RTKs) can activate class I PI3K through the binding interaction between the SH2 domains (Rous-sarcoma-oncogene homology-2 domains) of the p85 regulatory subunit with phosphorylated-tyrosine (pYXXM) motifs of the receptor, or via receptor associated adaptor molecules [94, 95]. The phospho-tyrosine (pY) – SH2 engagement releases imposed inhibition of p110 catalytic site, and them into close proximity to membrane resident lipid substrate phosphatidylinositol 4, 5,-biphosphate (PIP2) to generate phosphatidylinositol 3, 4, 5,-triphosphate (PIP3) [96-98].

Activation by RAS super family of G proteins

RAS activation of class I PI3Ks occurs through a direct binding with the RAS binding domain (RBD) of the p110 catalytic subunit [99-101]. However, activation is not uniform for all PI3K isoforms. Differential activation of PI3Ks is thought to be dependent on the particular RAS family members involved, or in the degree of activation among the PI3K isoforms, due in large part to the

marked sequence variation among the isoforms in the RBD of p110 [90, 102, 103]. The canonical activation of PI3K through RAS occurs in conjunction with activated RTKs, the recruitment of adaptor molecule growth factor receptor-bound protein 2 (GRB2) and the guanine nucleotide exchange factor (GEF) protein son-of-sevenless (SOS). This signaling complex both activates and brings RAS into proximity with p110 PI3K [100, 104]. RAS mediated activation of p110 α can be restricted by p85, however this inhibition can be released in response to p85 SH2 domain binding to (pY) motifs [105]. This suggests RAS activation of PI3K is a tightly orchestrated event, where p85 regulatory subunit can modulate responsiveness to RAS by sequential activation of catalytic subunits by RTKs, and that class IA PI3Ks may only be responsive to RAS after prior RTK activation.

G-protein-coupled receptor mediated activation of PI3K

The superfamily of heterotrimeric G-protein-coupled receptors (GPCRs) are cell surface signaling proteins involved in a wide range of physiological functions and diseases, including cancer development and metastasis [106]. Among the class IA PI3K isotypes, p110 β is uniquely found to be activated by GPCRs [107, 108]. Binding and activation of p110 β occurs through direct G $\beta\gamma$ heterodimer interaction with the catalytic p110 subunit occurring independently of p85 regulatory subunit [109, 110].

In addition to direct PI3K activation, the functional cross-talk between GPCRs and growth factor receptors is reported to contribute to the progression

of lung, breast, colon, prostate, and head and neck tumors by activation of PI3K [111]. Multiple GPCRs are found capable to transactivate EGFR signaling by promoting autocrine and paracrine release of EGF-like ligands [112, 113]. The GPCR-induced growth factor shedding is mediated by members of ADAM (a disintegrin and metalloproteinase) family of zinc-dependent proteases, most noteworthy being the tumor necrosis factor- α (TNF α) converting enzyme (TACE) [114]. Taken together, in solid tumors the GPCR driven PI3K signaling is mediated directly through the p110 β isoform, and can drive particular growth factor signaling upstream of PI3K by transactivation of receptor tyrosine kinases such as EGFR.

Effectors of PI3K signaling

The oncogenic nature of PI3K pathway signaling is the result of interactions that deregulate transcription and translation controls responsible for cell mass and cell cycle progression, as well as the direct modulation of pro-survival signaling [115]. Aberrant activation of PI3K/AKT signaling is a common feature to NSCLC, playing a critical role in the initiation and progression of the disease. [116-118]. The deregulated hyperactivation of AKT is observed in most NSCLC cell lines and NSCLC tumors [35, 36], and found to promote resistance to chemotherapy and radiotherapy [119, 120]. Recent characterization of AKT in lung cancer cell lines identified persistent activation of AKT attributed to PTEN loss, activating mutations in EGFR or PIK3CA, or amplification of ERBB2 [118].

The Ser/Thr kinase AKT (the mammalian homologue of the retroviral transforming protein v-Akt, or also known as PKB, due its homology to PKA and PKC) is the best studied effector of PI3K, as it was among the first proteins found to contain the pleckstrin homology (PH) domain required for phosphoinositide binding [121, 122]. The PH domain was shown to bind to phosphatidylinositol 4,5 P₂, and AKT is rapidly activated by growth factors and dependent on upstream PI3K lipid kinase activity [123]. The generation of phosphatidylinositol 3,4,5 P₃ and phosphatidylinositol 3,4 P₂ can directly bind to the PH domain of AKT allowing for activation phosphorylation at Thr308 by phosphoinositide-dependent kinase 1 (PDK1) [124-126]. However, initiating Thr308 phosphorylation is required for partial activation; an additional phosphorylation at Ser473 is needed for full AKT activation [127]. The phosphorylation at Ser473 is carried out by the mammalian target of rapamycin complex 2 (mTORC2) [128, 129].

Now 20 years since the discovery of AKT, we appreciate the central role as an effector of PI3K that is frequently activated in cancer leading to deregulated metabolism, proliferation and apoptosis (Figure 1.2.). The PI3K dependent activation of AKT occurs in 2 peaks affecting cell growth and G₁ cell cycle progression. The first occurs within minutes of growth factor stimulation (at the G₀/G₁ transition), and second occurring in advanced stage of G₁ phase [130-132]. Activated AKT has a number of direct substrates that have critical roles in transcriptional regulation of the cell cycle. Prominent examples are the cell cycle inhibitor protein p27 (also known as KIP1), the forkhead box transcription factors

(FOXO), glycogen synthase kinase 3 (GSK3), serum and glucocorticoid-induced kinase 1 (SGK1), tuberous sclerosis complex 2 (TSC2) and nuclear factor κ B (NF κ B) [133-135]. Upregulated PI3K/AKT signaling regulates cyclin-dependent kinase (Cdk) activity by inducing cyclin D synthesis and blocking its degradation, an effect directed by the inhibitory AKT phosphorylation of GSK3 β [136]. Cell cycle entry is mediated by PI3K/AKT signaling through FOXO transcription factor controlled expression of cyclin G2 and p27 [137, 138]. Another important molecule inactivated by AKT phosphorylation is TSC2, which functionally connects the activation of PI3K with mTOR signaling. Active TSC2 is unphosphorylated (Ser939 and T1462), whereby it heterodimerizes with TSC1 to negatively regulate GTPase activity of the Ras-like small GTP-binding protein RHEB [139, 140]. The active GTP-bound RHEB can directly interact to positively regulate mTORC1 (mammalian target of rapamycin complex 1) [141]. In addition to TSC2, AKT activates mTOR by phosphorylating regulatory protein subunit PRAS40 (proline-rich AKT substrate of 40kDa) (Ser246) to alter the inhibitory raptor-PRAS40 interaction [142].

The protein kinase TORC1 functions as an evolutionarily conserved environmental sensor. This multifunctional protein integrates to cellular energy and nutrient status and diverse environmental cues such as growth factors, hormones and mitogens to coordinate the proper homeostatic cellular responses. The PI3K/AKT activation of TORC1 promotes POL I- and POL III- RNA polymerase dependent transcription, thus regulating the abundance of protein synthesis machinery in the cell [143, 144]. Furthermore, mTORC1 can directly

regulate protein synthesis by phosphorylating effectors S6K (p70 S6 kinase) and 4EBP (translation initiation factor 4E-binding protein) proteins [145].

To date, TOR is known to exist as two multi-subunit complexes known as TORC1 (TOR complex 1) and TORC2 (TOR complex 2) [146]. These TORC complexes demonstrate distinct protein constituents, substrate specificity, regulation, and sensitivity to rapamycin [147]. The mammalian mTORC1 and mTORC2 assemblies both contain mTOR, mLST8 (mammalian lethal with SEC13 protein)/Gbl (G-protein β -protein subunit-like) and Deptor (EDP domain-containing mTOR-interacting protein). However, the interaction with Raptor and PRAS40 denotes mTORC1 complex, whereas the presence of Rictor, mSin1 (mammalian stress-activated MAPK-interacting protein 1) and p100 (protein observed with Rictor 1/2) are representative of the TORC2 complex [146, 148]. Little is known about the functional roles of the mTOR-associated proteins, however Raptor and Rictor proteins are established to function as molecular scaffolds needed for assembly of complexes, and PRAS40 is understood to be a functional suppressor of mTORC1 signaling [149]. As compared to mTORC1 the regulation and function of mTORC2 remains unclear. mTORC2 is responsible for phosphorylating AKT (Ser473), SGK1 (Ser422), and PKC α (Ser657) and is insensitive to rapamycin [150].

Downstream of mTORC1, the ribosomal protein S6K phosphorylates its own group of target proteins most of which are responsible for protein synthesis and regulation of cell size [148, 151]. The best studied target of S6K being rpS6 (ribosomal protein S6), an integral constituent of the 40S ribosome [152].

Concurrently, TORC1 promotes protein synthesis by phosphorylation of 4EBP1 which is responsible for initiating cap-dependent translation by eIF4E (eukaryotic initiation factor 4E) [149].

1.3 Activation of PI3K/AKT pathway in Lung Cancer

The PI3K pathway is commonly deregulated in lung cancer as a result of genetic modifications affecting one or more pathway components leading to hyperactive PI3K signaling [153]. Activation of PI3K in cancer is generally brought about by oncogenic RTKs acting upstream, K-RAS, PTEN loss, or mutations in PI3K itself. In lung cancers, multiple mutations are reported that control PI3K pathway activation, most notable are EGFR and K-RAS (discussed previously) and to a lesser extent by mutations in ERBB2, MET, PIK3CA, and PTEN.

EGFR and cognate ligands are frequently highly expressed in NSCLC occurring in approximately 40-80% of tumors [154], whereas activating kinase domain mutations comprise approximately 10-20% of tumors [155]. Activating mutations present in codons 12 and 13 of GTPase domain of KRAS are observed in approximately 15-25% of NSCLCs [156]. Combined, activating mutations affecting either EGFR and KRAS account for approximately 40-50% of all NSCLC cancers [157]. Crystal structures of the mutant EGFR harboring the TKI-sensitive L858R and G719S mutations show constitutive kinase active through disruptive auto inhibitory interactions [51, 158]. The constitutive signaling through mutant EGFR primarily activates PI3K/AKT and RAS/MAPK pathway

[159]. Lung cancers with mutant EGFR respond to TKI treatment with simultaneous abrogation of both of these survival/proliferation pathways inducing apoptosis and significant tumor regression. Whereas, KRAS-active lung cancers depend on signaling occurring downstream of EGFR and are therefore largely de novo resistant to TKI therapy.

Mutations in PI3K contribute by activating PI3K enzymatic signaling and therefore play an important role in tumorigenesis. A number of somatic mutations have been identified in the p85 regulatory subunit that lead to activation of all class IA isoforms leading to unregulated cell survival and proliferation, however tumor specific mutations in p85 remain largely unexplored. With respect to the catalytic subunit of class I PI3Ks, gain-of-function oncogenic mutations have only been identified in the p110 α (PIK3CA) isoform. Mutations in PIK3CA are common to a number of cancers in particular breast and colorectal cancers, and account for approximately 3% of NSCLCs [160-162]. Importantly, NSCLC tumors having PIK3CA mutations more frequently occur concurrent with EGFR or K-RAS (61.8%) mutations than alone (31.2%), and were mutually exclusive with loss of function mutations in PTEN [163, 164]. The co-existence of mutant EGFR and other molecular aberrations affecting IGF-1, PTEN, and PIK3CA were reported to decrease sensitivity to EGFR-TKIs [155, 165]. Likewise, the coexistence of these molecular alterations illustrates the difficulty with assigning individualized single-agent targeted treatments, and further highlights the potential benefit for combination therapies.

Although activating mutations of PIK3CA occur frequently in a number of cancers, the loss of PTEN phosphatase still remains the most common mechanism of activation of PI3K pathway found in human cancers [166, 167]. The genetic and/or epigenetic loss of PTEN phosphatase allows for uncontrolled PI3K kinase activity and activation of effector AKT signaling, resulting in unchecked proliferation and pro-survival signaling [168]. In both SCLC and NSCLC PTEN is rarely mutated, however considerable reduction in expression is common feature in lung cancers [169, 170]. Indeed, loss of PTEN expression and AKT overexpression confers poor prognosis in NSCLC [171]. Importantly, loss PTEN activity is found to contribute to erlotinib resistance in EGFR-mutant lung cancer by uncoupling AKT signaling from direct control of EGFR [172].

1.3.1 PI3K isoforms in cancer

Recent interest in the role of PI3K isoforms in cancer have revealed both unique and redundant functions related to tumorigenesis and signaling for the p110 α and p110 β isoforms, each of which represent the ubiquitous class IA catalytic subunits of PI3K residing in tissues of origin for most tumor types. p110 δ and p110 γ isoform expression is largely limited to cells of the immune system [75, 173]. The expression of p110 α and p110 β are essential for survival and each have non-redundant role with other class IA PI3Ks, as knockout mice demonstrate embryonic lethality at E9.5-10.5 and E3.5 for each respective isoform [174-176].

Both p110 α and p110 β isoforms are thought to play differential roles in transformation driven by alterations in particular components of the PI3K pathway and therefore have tumor specific activities. For example, tumors overwhelmingly receive PI3K activity through the p110 α isoform when harboring “hotspot” mutations in PIK3CA or ERBB2 mutations such as those commonly found in breast and bladder cancers [177, 178]. Whereas, PTEN-null cancers which are common in tumors of the prostate and glioblastoma are thought to be mediated through p110 β [179-183]. This divergence is further evident in that mutations affecting PIK3CA and PTEN rarely co-exist in the same cell, and thought to be mutually exclusive [184, 185]. Tumors with mutant PIK3CA often possess alterations in other components of the PI3K pathway such as RAS, and ERBB2/ERBB3 [178, 186]. Pharmacological and knockdown studies confirm signaling to AKT is directed by 110 α in breast, colon, and endometrial cancers having co-existing mutations of PIK3CA with RAS or ERBB2/ERBB3 [187].

The hotspot mutations in p110 α have been found to cluster in two locations, the helical domain (E542K and E545K) and the in the C-lobe of kinase domain (H1047R) [161, 188]. The helical domain mutations prevent the regulatory interaction of p85 nSH2 domain by disrupting electrostatic interactions between helical residues and nSH2 [189]. Activation of helical domain mutants is no longer responsive (pY) phosphopeptides, but are still dependent on RAS to induce oncogenic transformation [190, 191]. The most common PIK3CA mutation in lung cancer, H1047R, which affects the C-lobe kinase domain conformation of α 4- α 5 and α 11- α 12 loops responsible for membrane

interaction are likely oncogenic due to increased membrane association [192]. Consistent with this observation, the H1047R mutants do not require RAS activation for oncogenic transformation because the adoption of semi-activated conformation of the kinase domain due to constitutive membrane localization [193].

Paradoxically, apart from p110 α (PIK3CA), no other oncogenic mutations have been identified in any of the other class I PI3K catalytic isoforms. Furthermore, the transformative capacity of chicken embryo fibroblasts (CEFs) differs between the E545K and the H1047 PIK3CA mutants, and among the class IA isoforms. Transformation required overexpression of a mutant variant for p110 α , as compared to isoforms p110 β , δ , and γ which are inherently oncogenic when expressed in as wild-type proteins [194]. Elegant studies using p110 α/β chimeras to analyze the C2-iSH2 brake demonstrated that disruption of this inhibitory interface is partially responsible for transforming potential of wild-type p110 β and is the likely cause of high basal p110 β signaling [110]. However, in the same study p110 δ demonstrated differing characteristics in regards to the intact C2-iSH2 interaction, thus indicating a higher order factors are responsible for p110 δ wild type transforming potential [110]. The disruption of this p85:p110 inhibitory contact may also explain the failure for p110 β effectively signal downstream of activated RTKs relative to p110 α as wild-type proteins [107].

The frequency to which PIK3CA is activated in human cancers, and the important role PTEN plays as the negative regulator of PI3K pathway activation, it could be assumed that p110 α would function as the dominant isoform signaling

downstream of PTEN loss. Rather, a number of recent studies put that assumption into question by identifying the catalytic activity of p110 β as the essential isoform for signaling and growth of PTEN-null cancers [181-183, 195]. This work has been validated using PTEN-null human cancer cell lines for prostate, brain and breast where researchers found that the both pharmacological inhibition using isoform-selective inhibitors of p110, and genetic knockdown of p110 β , not p110 α impaired downstream activation of AKT. Although controversial, a recent study has implicated p110 β in specific growth of ERBB2-driven mammary tumors and K-RAS driven tumors [195]. Finally, p110 β is the only class IA PI3K that signals downstream of GPCRs. This occurs via direct interaction with p110 β catalytic subunit and G $\beta\gamma$ subunit, and activation occurs independent of the p85 regulatory subunit [196]. Although these studies demonstrated that p110 β plays a dominant role in PI3K signaling in PTEN-deficient tumors, it is likely that this reliance is determined by the signaling inputs and the genetic context. Likewise, the contributions of GPCR-driven tumors and the relationship with p110 β signaling remains elusive, but may hold promising opportunities. It is clear that p110 α and p110 β demonstrate distinct and overlapping functions in cell signaling and tumorigenesis, continued investigation is needed as both pan-isoform and isoform-selective PI3K inhibitors move into the clinic.




Figure 1.3. Chemical structures of pan-class I and isoform-selective PI3K inhibitors. LY294002 was the first synthesized PI3K inhibitor. ZSTK474 is a pan-class I PI3K inhibitor. A66, TGX-221 and CAL-101 are isoform-selective inhibitors of p110 α , p110 β , p110 δ respectively.

Clinical development and therapeutic limitations of PI3K inhibitors

Unfortunately, the majority of PI3K pathway inhibitors are currently in early clinical development, thus a paucity of clinical data for efficacy and toxicity. PI3K inhibitors fall into 3 general categories: pan-class I PI3K, isoform-selective and dual PI3K/mTOR inhibitors. The first generation of PI3K inhibitors were pan-class I inhibitors, the natural compound wortmannin and the first synthesized drug LY294002 [197, 198]. These drugs demonstrated potent in vitro activities against PI3K signaling, however both showed considerable toxicities in animal studies and failed to reach clinical evaluation. Notwithstanding, more than 15 different agents are currently in various stages of clinical evaluation, a number of which utilize the functional aryl morpholine moiety present in LY294002 [199-201] (Figure 1.3.). Among those currently being investigated, early indications suggest that pan-PI3K/mTOR inhibitors may demonstrate the greatest clinical promise.

The advantage of pan-PI3K/mTOR inhibitors is a more complete shutdown of the PI3K/AKT/mTOR signaling axis, which may remain active in some cancers capable of bypassing single isoform or pan-PI3K, AKT, and mTOR inhibitors related feedback activation of the pathway [202-210]. Continued research is needed to define the innate and acquired mechanisms of resistance that reconstitute PI3K signaling or activate parallel pathways during inhibitor treatment. PI3K and mTOR are structurally similar, both belonging to the PI3K-related kinases (PIKK) superfamily, and therefore similarly targeted by certain inhibitory compounds [82]. Preclinical in vitro studies suggest pan-PI3K/mTOR inhibitors have broader efficacy across a variety of genotypes as compared to

pan-PI3K or mTOR targeting rapamycin analogs [202, 211, 212]. NVP-BEZ235 was the first member of the pan-PI3K/mTOR class of inhibitors to enter phase I clinical trials in patients with advanced solid tumors [213]. However, problems with increased toxicity may prove pan-PI3K/mTOR inhibitors are unsuitable for some genetic contexts or use in combination therapies. Currently, we are unable to make the side by side comparison of clinical efficacy and toxicity between dual pan-PI3K/mTOR and pan-PI3K inhibitors due to lack of clinical data. One may speculate that pan-PI3K inhibitors, having improved specificity relative to dual pan-PI3K/mTOR inhibitors, may be better suited for combination regimens with other targeted or chemotherapeutic agents. According to the ClinicalTrials.gov database, currently there a total of 19 combination trials using pan-PI3K inhibitors plus chemotherapy, and 9 reported for PI3K/mTOR inhibitors with chemotherapy.

Isoform-selective PI3K inhibitors are in clinical development with the goal of targeting specific alterations in PI3K while circumventing off target toxicity associated with inhibiting multiple isoforms. In particular are the development of p110 α specific inhibitors to target tumors driven by activating PIK3CA mutations, and p110 δ selective inhibitors for hematological malignancies. As compared to pan-PI3K isoform inhibitors, isoform-selective inhibitors of PI3K have a more narrow activity profile among differing tumor types and will require careful patient selection based upon biomarkers of sensitivity [214]. The emergence of isoform-selective inhibitors of PI3K, and the perceived decrease in toxicity raises the possibility of combining these agents with other targeted inhibitors. The use

of isoform-selective PI3K inhibitors with other targeted agents may offer more personalized therapeutic option as compared to a use with pan-PI3K inhibitors.

Recently development and preclinical characterization of p110 α selective inhibitors have shown differential patterns of sensitivity and resistance related to the genetic context. The effects of p110 α selective inhibitor BYL719 treatment in a large panel of cancer cell lines indicated sensitivity in tumors harboring PIK3CA activating mutations or amplifications or HER2 amplifications, but resistance in those with PTEN and BRAF alterations, and coexisting PIK3CA and KRAS mutations [215, 216]. Furthermore, results from phase I clinical trials with p110 α selective inhibitors (BYL719 and GDC-0032) suggest potential benefit for these agents in selective tumors bearing PIK3CA mutations [217, 218]. In contrast with p110 α selective inhibitors, recent studies suggest tumors having loss of function PTEN mutations are sensitive to p110 β selective inhibitors. Currently there are three p110 β selective inhibitors in early clinical trials, AZD8186, GSK2636771, and SAR260301 for treatment of advanced solid tumors with PTEN deficiency [219-221].

The p110 δ inhibitor CAL-101 (GS-1101) is the best studied isoform-selective PI3K inhibitor to date. Currently in phase III trials, CAL-101 is being investigated for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The success of CAL-101 has provided the proof of concept that isoform-selective PI3K inhibition may be clinically relevant if acting in the appropriate cellular context. The p110 δ isoform is primarily expressed in neutrophils, monocytes and lymphocytes, as well as lymphoid tissues such as the thymus,

lymph nodes and spleen, thus playing a central role in immune signaling through PI3K [222]. Targeting p110 δ impairs signaling known to promote CLL migration and retention in bone marrow and/or lymphoid tissues, as well as directly block proliferation and survival of these cells. Collectively there are three p110 δ selective inhibitors in development, CAL-101 (GS-1101), AMG 319, and IC488743 (GS-9820) for treatment of lymphoid malignancies.

1.4 PROJECT OVERVIEW

The PI3K pathway is firmly established a major conduit for tumor proliferation and survival and is actively involved in the development and progression of lung cancers. Thus, inhibitors of PI3K may be useful as a cytotoxic or sensitizing agents for treatment of NSCLC. Although inhibitors of the pathway are currently in clinical trials, rational and targeted use of these compounds, alone or in combination, requires an understanding of isoform specific activity in context. In this body of research, the ultimate goal is to evaluate the therapeutic potential for isoform-selective inhibitors through detailed study of PI3K pathway activation, proliferation, and survival in a lung cancer model system.

An overarching question to which this dissertation addresses is whether single-agent PI3K inhibitors can be clinically effective cancer therapeutics. To date, most all clinically successful targeted therapies have been targeted inhibitors against tyrosine kinases, such as BCR-ABL, KIT, EGFR and ERBB2. The common thread among these is that target inhibition leads to the

downregulation of multiple signaling pathways, not just one as is the case with PI3K. One major limitation of single-agent PI3K inhibitor effectiveness is the presence of negative feedback signaling and pathway crosstalk. Prominent examples being the feedback observed with rapamycin treatment where mTORC1 impairment leads to reactivation of PI3K signaling through a feedback inhibition of IGF-1 and the extensive cross pathway regulation between constituents of PI3K and ERK pathways [203]. Given this, there is compelling rational for combining PI3K pathway inhibitors with other targeted therapies to improve clinical efficacy.

To address these questions, the following testable hypothesis were proposed. **First, individual class IA PI3K isoforms p110 α , p110 β , and p110 δ represent novel targets for therapeutic intervention in mutationally diverse NSCLC. Secondly, therapeutic sensitivity and resistance to PI3K inhibition are mediated by pathway compensation due to presence of coexisting mutations, which can be overcome by combination treatment of targeted inhibitors.** Together this work delineates the activity of PI3K in mutationally-defined NSCLC, discovered through the use of pan-class I and isoform-selective inhibitors of PI3K may direct the clinical use of PI3K inhibitors as a single-agent or in combination with EGFR-TKIs for select patient populations.

CHAPTER 2

2.1 OVERVIEW

Lung cancer leads to the greatest morbidity and mortality of all cancer deaths in the United States [19]. To combat these diseases, new therapeutic agents and therapeutic strategies are necessary, and these strategies should include patient-specific therapy to minimize toxicity and cost. Targeting therapies to actionable mutations found in non-small cell lung carcinomas (NSCLC), such as mutation/amplification of epidermal growth factor receptor (EGFR) gene [223], activating point mutations in p110 α isoform of PI3K (PIK3CA) [224], and in the KRAS gene [225], and deletion of the PTEN gene [172], may help achieve personalized treatments. Importantly, each of these genetic alterations can lead to increased survival signals that converge on the PI3K/AKT/mTOR cascade. While the PI3K pathway is a central node for control of both cell growth and cell proliferation in normal epithelial cells, aberrant pathway activation in lung tumorigenesis dysregulates cell metabolism, proliferation, apoptosis, and angiogenesis [226-228].

Many cancers depend on a hyperactive PI3K pathway. Thus, increased attention has been placed on development of pharmacological inhibitors of PI3K enzymes that are often mutated or improperly expressed in tumors [229]. Specifically, activation of class IA PI3Ks generates plasma membrane lipid second messenger molecules by phosphorylating the 3'-OH position of phosphatidylinositol 4,5 bisphosphate (PIP₂) to produce phosphatidylinositol-3,4,5-trisphosphate lipid (PIP₃). While PIP₃ levels are tightly regulated by the

cell, net pathway activation is determined by a delicate balance between the opposing activities of PI3K lipid kinases and 3- and 5- lipid phosphatases such as PTEN. Recent evidence suggests that there are specific cellular contexts and physiological roles for each class IA PI3K isoform: p110 α (PIK3CA), p110 β (PIK3CB), and p110 δ (PIK3CD) [230, 231]. Cell-specific activities of PI3Ks include selective recruitment of p110 isoforms to activated receptors and second-messenger signal diversification by interaction with various PI3K p85 isoforms. Additionally, activated receptor tyrosine kinases, G-protein coupled receptors, RAS and other small GTPases can signal through cell type-specific PI3K isoforms [107, 181, 182, 232-234]. Application of these data to drug discovery efforts revealed a role for PIK3CD inhibition for treatment of B-cell malignancies and autoimmune diseases [235, 236]. Finally, class IA PI3Ks may also possess non-catalytic activity, serving as molecular scaffolds for other signaling proteins. Thus, therapeutic targeting of individual PI3K class IA proteins may have clinical promise in solid tumors by impeding a host of PI3K functions necessary for cancer cell growth.

We hypothesized that PI3K isoform-selective inhibitors would have clinical value for personalized treatment of lung cancers. Herein, we describe the effects isoform-selective inhibition of class IA PI3K enzymes on pathway activation, proliferation, and viability in genetically-diverse NSCLC cell lines. Our results show that differences in PI3K isoform mutation status, signaling pathway mutations and/or amplifications, and importantly, the apparent compensatory

activity of PI3K isoforms may be critical considerations for personalizing cancer therapy using PI3K inhibitors.

2.2 METHODS

Cell Lines and Culture Conditions

Human NSCLC cell lines obtained from American Type Culture Collection were A549, H460, H1650, H1975, and PC9. The lines were frozen at low passage for future use and subsequently were confirmed by STR testing (Bio-synthesis Inc, Lewisville, TX.). All cell lines were propagated as monolayer cultures at 37°C in 5% CO₂ using growth media containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS), glucose, sodium pyruvate, HEPES buffer and penicillin-streptomycin (Life Technologies, Grand Island, NY). The mutational status of each cell line (<http://www.sanger.ac.uk/genetics/CGP/cosmic/>) is found in Figure 2.1. A.

Reagents

IC488743 and CAL-101 (GS-1101) were provided by Gilead Sciences (Foster City, CA). A66, TGX-221, and ZSTK474 was purchased from Selleckchem (Houston, TX). All inhibitors were dissolved in DMSO (Sigma Aldrich Corp, St. Louis, MO; BP231-100) to a stock concentration of 10mM, stored at -20C, and diluted to indicated final concentration in RPMI 1640 containing FBS at time of use.

PI3K activity ELISA

PI3K isoform inhibitor specificity was determined in vitro using an ELISA assay (Millipore, Billerica, MA; 17-493) according to manufacturer's instructions. The biotinylated-PIP3 well values are set to 100. Experimental signals are divided by biotinylated-PIP3 then multiplied by 100 to give percent positive signal. IC₅₀ values and growth curves were calculated using Graphpad Prism software. Figures represent percent relative to control for each drug/isoform concentration as indicated. For detailed instructions, refer to the following document:

[http://www.millipore.com/userguides.nsf/a73664f9f981af8c852569b9005b4eee/ca49bfd0cd79e94b852577c3007bcebd/\\$FILE/PI3K.pdf](http://www.millipore.com/userguides.nsf/a73664f9f981af8c852569b9005b4eee/ca49bfd0cd79e94b852577c3007bcebd/$FILE/PI3K.pdf)

Cell Proliferation Assessment

The growth inhibitory activity of each compound was tested on cells using the Alamar Blue viability and Trypan Blue exclusion assays [237, 238]. In the Alamar Blue assay, cell lines were plated at 2×10^3 cells/well in 96-well cell culture plate (USA Scientific, Ocala, FL; CC7682-7596), then were treated 24 hr later with PI3K inhibitors) for 72 hr diluted in RPMI 1640 containing 1% serum. For the Trypan Blue exclusion assay, cells were plated at 1×10^4 cells/well in 24-well cell culture plate (USA Scientific, CC7682-7524). The cells were synchronized 24 hr later by changing media to RPMI containing 0.1% serum. After 24 hr serum deprivation, cells were released in RPMI containing 1% serum with PI3K inhibitors for 72 hr. Cells were trypsinized, and mixed 1:1 with trypan

blue for visual counting of both viable and dead cells. Experimental concentrations from (0.3 - 30 μ M) of A66, TGX-221, IC488743 and CAL-101 were tested. GI₅₀ values were calculated using Graphpad Prism software.

Cell Cycle and Apoptosis Analysis

For the cell cycle study, NSCLC cell lines were plated in 60-mm dishes (Corning, Corning, NY; 25382-381). After 24 hr, the cells were treated with ZSTK474 and IC488743 at the indicated GI₇₅ concentrations for 24 and 48 hr. Following incubation, cells were trypsinized, quenched with serum, washed, resuspended in phosphate buffered saline (PBS), and fixed in cold 70% ethanol. Cell cycle distribution was assessed by staining with propidium iodide (PI) and evaluated by BD FACS Calibur flow cytometry. Data were analyzed with CellQuest software (BD Biosciences, San Jose, CA). Analysis of apoptosis was performed using the same conditions as the cell cycle study, where whole-cell lysates were analyzed by western blot analysis for cleavage of PARP as described below (Cell Signaling Technology, Danvers, MA).

Analysis of Protein Expression

NSCLC cells were plated in 60-mm dishes. After 24 hr, plating media was removed, and cells were synchronized in starvation media RPMI 1640 containing 0.1% FBS for 24 hr. Concentration-dependent response experiments were carried out using indicated drug concentrations for 3 hr. Similarly, time-dependent response to drug exposure was undertaken at 1 μ M concentration of

each isoform-selective inhibitor at indicated time intervals. After drug treatment, cells were harvested, pelleted by centrifugation, and lysed with M-PER protein extraction reagent (Thermo Fisher Scientific, Waltham, MA; 78503).

Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes for antibody exposure. Signal was elicited using chemiluminescent reagents (ThermoScientific/Pierce). Primary antibodies used in these experiments were phospho-AKT (Ser473), total AKT, phospho-ERK1/2 (Thr302/Tyr204), total ERK1/2, phospho-S6 ribosomal protein (pS6RP) (Ser235/236) phospho-GSK3B (Ser9), α -tubulin, PTEN, LC3 β , PARP, p85, cyclin D1, HSP90, Histone H3, PI3K p110 α , p110 β (Cell Signaling Technology, Danvers, MA; 9271, 9272, 9101, 4695, 4858, 5558, 2125, 9559, 2775, 9532, 9661, 4255, 3011, respectively) and PI3K p110 δ (Santa Cruz Biotechnology, Santa Cruz, CA; sc-7176).

Cytosolic and Nuclear Protein Extraction

A549, PC9 and H1650 NSCLC cell lines were treated with indicated concentrations of agents, representing the estimated GI₇₅ concentrations for IC488743 and ZSTK474. After 48 hr exposure cells were trypsinized, quenched with serum, pelleted, and washed once with PBS. Nuclear and cytosolic compartments were separated according to NE-PER Nuclear and Cytoplasmic Extraction Kit protocol (ThermoScientific/Pierce, 78835). Western blot analysis for cyclin D1, and controls for cytosolic and nuclear fractionation, HSP90 and Histone H3, were performed as described above.

Short Interfering RNA Knockdown (siRNA)

Cells were plated in 6-well dishes in growth medium without antibiotics. After 24 hr and immediately prior to transfection, the media was changed to RPMI 1640 containing 1% FBS without antibiotics. Using isoform-specific PI3K p110 β siRNA (Smartpool-Dharmacon, Thermo Fisher Scientific, Waltham, MA; L-003019-00) (25 nM) was pre-incubated with RNAiMAX transfection reagent (Life Technologies, 13778-150) then added to cells for 24 hr. siRNA-containing media was replaced with RPMI 1640 containing 1% serum with or without 1 μ M CAL-101 or IC488743 for 3 hr. Cells were then harvested and extracts prepared for western blot analysis, as previously described in analysis of protein expression.

Statistical analyses

Cell proliferation assays were completed three times with three replicates per experiment (Figure 2.2., Table 2.2.). The technical replicate values were averaged for the three experiments and plotted, mean \pm standard deviation (SD). ELISA experiments were completed once with technical replicate measures. IC₅₀ values were calculated using Graphpad Prism.

Pharmacodynamic analysis represents three independent experiments quantified by densitometric analysis, pAKT (S473) normalized to tAKT, and averaged to reflect changes in pAKT levels (Figure 2.3.). Image J software was used for densitometric analysis of pAKT and tAKT levels from films. The error bars for each agent and cell line combination represents the SEM, n=3.

Cell cycle and apoptosis data represent the mean \pm SD of 3 separate experiments, (Figure 2.6.). Figures were generated using Graphpad Prism. Pearson correlation calculation was performed using GraphPad Prism software to compare paired GI₅₀ values for each inhibitor quantified in serum-synchronized cells vs. asynchronous cells. The r-value represents the correlation coefficient.

2.3 RESULTS

PI3K isoform expression levels or mutation status alone do not dictate response to PI3K inhibitors.

We initiated the experimentation by determining the expression levels at the gene and protein level for class IA PI3K enzymes in a panel of NSCLC cell lines (Figure 2.1.). Gene expression levels of PI3K isoforms was measured in NSCLC cells using Affymetrix DNA microarray technology. Normalized Affymetrix signal intensity values revealed that the p110 β isoform is the most highly expressed of the three isoforms assayed while the p110 δ isoform was poorly expressed. Expression of important pathway members was also determined. PTEN demonstrated varying levels of expression among cell lines [239]. Even though gene expression levels vary among PI3K isoforms, levels of protein expression for PI3K isoforms change only modestly (Figure 2.1. B). PTEN expression is the most variable among pathway members assessed. All cell lines show activation of AKT (S473) and varying levels of activated ERK1/2. Finally, mutation status for important driver mutations (EGFR, KRAS, PIK3CA, or PTEN) is also indicated for the cell lines utilized.

To assess the contribution of each class IA PI3K enzyme in lung cancer cells to proliferation and AKT phosphorylation, we chose pharmacological inhibitors of PI3K isoform activity. Inhibitors of three chemotypes previously shown to possess isoform-selective activity were selected: A66 (aminothiazole) [240]; TGX-221 (morpholinochromone) [241]; CAL-101 (quinazolinone purine) [242], and IC488743 [243] (Table 2.1). Briefly, A66 preferentially inhibits p110 α , TGX-221 preferentially inhibits p110 β isoform, CAL-101 and IC488743 are potent p110 δ inhibitors, and the latter also had significant inhibitory activity against p110 β . We used the pan-PI3K inhibitor, ZSTK474, which has low nanomolar IC₅₀ values for all three class IA isoforms as a control [244]. Although the IC₅₀ values for these inhibitors have been independently reported [240-243], we quantified the kinase activity of A66, TGX-221, CAL-101 and IC488743 using a uniform ELISA assay (Figure 2.2.). The resulting IC₅₀ values are consistent with those previously reported (Table 2.1.).

To determine whether isoform-selective PI3K inhibitors affect NSCLC cell proliferation and survival, Alamar Blue and Trypan Blue exclusion assays were used. We tested both cell lines in asynchronous and synchronized growth conditions to determine if cell cycle position affected activity of the agents. First, asynchronously growing cells were treated for 72 hr with the pan-PI3K inhibitor, ZSTK474, or each of four isoform-selective inhibitors to determine the half-maximal concentration for growth inhibition (GI₅₀) using the Alamar Blue assay (Table 2.2., Figure 2.3.). In cells synchronized by serum starvation, treatment with PI3K inhibitors was carried out for 72 hr and assayed by Trypan Blue

exclusion (Appendix I: Table 2.3.). There was significant agreement between inhibition of asynchronous and synchronous cells as determined by match-ranking of the inhibitors based on the calculated GI_{50} ($r= 0.651$, $p= 0.001$).

In summary, pan-PI3K isoform inhibition with ZSTK474 was effective at blocking proliferation in all NSCLC cell lines achieving GI_{50} values at nanomolar concentrations. Treatment with isoform-selective inhibitors for p110 α , p110 β , and p110 δ enzymes was largely ineffective at impairing proliferation at concentrations conferring isoform selectivity. H460 and H1975 cells have the greatest sensitivity to the PIK3CA inhibitor, A66 (GI_{50} 8.1 μ M and 1.7 μ M) and demonstrated the greatest overall responsiveness PI3K inhibition compared to other cell lines tested. Conversely, PC9 and H1650 cell lines were found to be the least sensitive to all PI3K inhibitors tested. In particular, PC9 cells are most resistant to TGX-221 and CAL-101 ($GI_{50} >100\mu$ M), and H1650 cells are most resistant to A66 ($GI_{50} >200\mu$ M). Finally, cell cycle position does not appear to alter sensitivity in any cell line.




Figure 2.1. Expression of class IA PI3K p110 isoforms and PTEN among NSCLC cell lines. (A) Relative mRNA expression of p110 isoforms and PTEN were measured by Affymetrix microarray analysis. NSCLC cell line mutation status and histopathology are indicated below as Adenocarcinoma (AD) and Large cell carcinoma (LC). **(B)** PI3K p110/p85 isoform and pathway effector protein expression in NSCLC cell lines was determined by immunoblotting analysis. Experiments were performed using sub-confluent proliferating cells maintained in 10% serum containing media.




Figure 2.2. Inhibitor specificity measured by Class IA PI3K isoform activity ELISA. PI3K isoform inhibitor specificity was determined in vitro using an ELISA assay according to manufacturer's instructions. Points represent the average of replicate wells in single experiment. IC₅₀ values indicating drug selectivity for each of the PI3K isoforms p110 α , β and δ are found in table below each plot (μ M).

IC₅₀ (μM)	p110α	p110β	p110δ	p110γ	mTOR
Pan-PI3K inhibitor					
ZSTK474	0.017	0.053	0.046	0.049	>10
Isoform-selective PI3K inhibitors					
A66	0.032	>12.5	>1.25	3.48	>50
TGX-221	5	0.005	0.100	>35	>10
CAL-101	0.82	0.56	0.002	0.089	>1
IC488743	>20	1.2	0.005	-	-

Table 2.1. PI3K inhibitor IC₅₀ selectivity profile. Table indicates previously published biochemical selectivity's for the class I PI3K isoforms and mTOR for each inhibitor tested in study (μM).

GI₅₀ (μM)	A549	H460	H1975	PC9	H1650
Pan-PI3K inhibitor					
ZSTK474	0.33	0.15	0.21	0.40	0.69
Isoform-selective PI3K inhibitors					
A66	15.64	8.10	1.74	23.31	>200
TGX-221	24.19	26.78	21.88	120.5	50.14
CAL-101	22.09	10.66	10.85	131.6	62.10
IC488743	22.80	17.45	14.28	32.15	24.45

Table 2.2. GI₅₀ values of PI3K inhibitors for NSCLC cell lines. A549, H460, H1975, PC9, and H1650 were treated with increasing concentrations of PI3K inhibitors: ZSTK474, A66, TGX-221, IC488743, and CAL-101 for 72 hr (0.03 - 100μM). Cell proliferation was determined by Alamar Blue viability assay. Non-linear curve fitting and GI₅₀ values were generated using Graphpad Prism.




Figure 2.3. Growth inhibition activity PI3K inhibitors against a panel of 5

NSCLC cell lines. A549, H460, H1975, PC9, and H1650 were treated with

increasing concentrations of PI3K inhibitors: ZSTK474, A66, TGX-221,

IC488743, and CAL-101 for 72 hr (0.03 - 100 μ M). Cell proliferation was

determined by Alamar Blue viability assay. Each experiment was performed with

triplicate cultures, for 3 independent experiments (n=3). Error bars represent

standard deviation (SD). Experimental results were normalized to 24 hr plated

cells and divided by untreated control to determine (% growth relative to control).

Non-linear curve fitting and GI₅₀ values were generated using Graphpad Prism.

Inhibition of PI3K/AKT blocks survival signals necessary for proliferation

To assess whether the lack of proliferative response of the cell lines to isoform-selective inhibitors of the PI3K enzymes was due to inadequate target inhibition, we tested AKT activation over a range of inhibitor concentrations by western analysis of serine 473 phosphorylation after 3 hr of treatment. The ratio of pAKT/tAKT was determined by densitometric evaluation of the immunoblots and is plotted for each cell line and isoform-selective inhibitor at indicated concentrations (Figure 2.4.).

Consistent with the proliferation assays, H1975 and H460 cell lines demonstrate the greatest reduction of pAKT at nanomolar concentrations of A66 while H1650 demonstrated only minor reduction in pAKT even at high concentrations (Figure 2.4. A). Treatment with the p110 β inhibitor, TGX-221, had little effect on AKT phosphorylation in all cell lines except for the H1650 cells (Figure 2.4. B). H1650 cells demonstrated nearly 75% reduction in pAKT at nanomolar levels of TGX-221. Treatment with the p110 δ inhibitors (CAL-101 and IC488743) reduced AKT phosphorylation below 50% at the highest concentrations used for most cell lines (Figure 2.4. C and 2.4. D). As compared to the isoform-selective inhibition, treatment with the pan-class I PI3K ZSTK474 was followed by complete loss of pAKT at all concentrations except for at 0.1 μ M, whereby we achieve >50% decrease in all cell lines tested (Figure 2.5.). We did not observe any change in pERK1/2 phosphorylation in response to 3 hr ZSTK474 treatment.

Recent studies identify the catalytic activity of p110 β as the essential isoform for signaling and growth of PTEN-null cancers, we sought to further validate these findings by testing the isoform-selective inhibitors utilized in this study in the PTEN-null prostate cancer cell line, PC3 (Figure 2.6.). We note activated PI3K/AKT signaling and basal expression levels of class IA PI3K isoforms at similar levels to those found in NSCLC cell lines. As indicated by the pharmacodynamic and proliferative responses to isoform-selective inhibitor treatment, PC3 cells demonstrated the greatest sensitivity to the p110 β inhibitor, TGX-221, and were least responsive to the p110 α inhibition. Treatment with the p110 δ inhibitors were able to diminish pAKT signaling, but had limited effects on proliferation.

To determine the duration of inhibition of effector molecule (pAKT and pS6RP) phosphorylation, a time course was performed with 1 μ M of each inhibitor on three NSCLC lines (A549, PC9, H1650) (Figure 2.7.). At this concentration (1 μ M), each compound is predicted to be largely on-target, having a minor impact on other PI3K isoforms. The duration of activity was consistent with both the proliferation and concentration-dependent treatment assays. Specifically, the effect of each inhibitor against A549 cells was sustained over time, as measured by reduction in phosphorylation of AKT and S6. The PC9 cells displayed minimal response to each agent demonstrated by uninterrupted pAKT levels, except for A66. However, like the other cell lines, pS6 was reduced over time with each inhibitor relative to untreated cells. Like PC9 cells, H1650 cells also demonstrated sustained responses to each agent as measured by absence of S6

phosphorylation. However, A66 is ineffective at reducing pAKT levels, unlike other agents relative to the untreated control. The accumulated data suggest that loss of a single PI3K class I isoform might be compensated by remaining isoforms. To test this hypothesis, we undertook an experiment to couple gene depletion with pharmacological treatment.




Figure 2.4. Pharmacodynamic responses to PI3K isoform-selective

inhibition. The relative levels of phosphorylated AKT in NSCLC cell lines (A549, H460, H1975, PC9, H1650) treated with increasing concentrations (0.1-10μM) of PI3K inhibitors **(A)** A66 **(B)** TGX-221 **(C)** CAL-101 and **(D)** IC488743. Cells were synchronized by serum-starvation for 24 hr prior to release in RPMI 1640 media containing 1% serum with or without drug for 3 hr. Cell lysates were collected for immunoblotting analysis with pAKT (S473) and tAKT antibodies. α -tubulin serves as the normalization control. ImageJ software was used for densitometric analysis of pAKT and tAKT levels. Three independent experiments were quantified, pAKT (S473) was normalized to tAKT, and data were averaged to reflect relative changes in pAKT (S473) activation. Error bars represent mean \pm SEM. PI3KCA mutant cell lines are indicated.




Figure 2.5. Pharmacodynamic responses to pan-class I PI3K inhibitor

ZSTK474. The relative levels of phosphorylated AKT in NSCLC cell lines (A549, PC9, and H1650) treated with increasing concentrations of ZSTK474 (0.1-10μM). Cells were synchronized by serum-starvation for 24 hr prior to release in RPMI 1640 media containing 1% serum with or without drug for 3 hr. Cell lysates were collected for immunoblotting analysis with pAKT (S473), tAKT, pERK1/2, tERK and α-tubulin antibodies.




Figure 2.6. Basal class IA PI3K expression, proliferation and pharmacodynamic responses to isoform-selective inhibitors in PTEN-null prostate cancer cell line PC3. (A) Class IA p110 isoform and pathway effector protein expression as determined by immunoblotting analysis. Proliferating cells in 10% serum containing RPMI were harvested 24 hr after plating. **(B)** PC3 cells were treated with increasing concentrations of PI3K inhibitors; A66, TGX-221, IC488743, and CAL-101 for 72 hr (0.03 - 30μM) and proliferation was determined by Alamar Blue viability assay as described previously. **(C)** The relative levels of phosphorylated AKT after treatment with increasing concentrations of A66, TGX-221, CAL-101 and IC488743. Cells were synchronized by serum-starvation for 24 hr prior to release in RPMI 1640 media containing 1% serum with or without drug for 3 hr. Cell lysates were collected for immunoblotting analysis with pAKT (S473), tAKT, and α-tubulin antibodies.




Figure 2.7. Isoform-selective PI3K inhibitor treatment demonstrates sustained time-dependent inhibition of PI3K signaling. A549, PC9 and H1650 cells were treated with 1 μ M isoform-selective inhibitors in RPMI 1640 containing 1% serum for regular time intervals of 1, 6, 12, 24, 48, 72 hr after drug addition. Untreated controls were tested using identical conditions but without drug addition. Samples were collected at each time point for immunoblotting with indicated antibodies as described above. α -tubulin serves as the normalization control.

siRNA knockdown of p110 β does not phenocopy effects observed with PIK3CB and D inhibition.


The previous experiments provided evidence that inhibition of proliferation and loss of AKT signaling manifested at concentrations of each inhibitor that exceeded selectivity for a single isoform. Only the pan-inhibitor, ZSTK474, was effective at inhibiting proliferation at sub-micromolar concentrations, suggesting that in most cells PI3K activity was necessary. Further, the cell lines with activating PIK3CA mutations (H460 and H1975) were the most sensitive to A66, as previously described in the breast cancer literature [218, 245, 246]. We hypothesized that PI3K isoforms may be able to compensate for one another. We tested this hypothesis on the cells least sensitive to PIK3CA pharmacological inhibition (A549, PC9, H1650). Expression of p110 β was ablated using short-interfering RNA (siRNA) then cells were treated with either CAL-101 or IC488743 for 3 hr at 1 μ M concentration.

Silencing of p110 β isoform reduced expression of p110 β in A549 by 80%, in PC9 by 55%, and in H1650 by 61%, as measured by densitometry (Figure 2.8. A). However, partial ablation of the p110 β isoform alone did not significantly reduce phosphorylation of AKT at S473 compared with IC488743 or CAL-101 treatment alone in all cells, suggesting that p110 α and p110 δ isoforms, or residual p110 β , can compensate for the genetic loss of p110 β . Importantly, the observed decrease in pAKT after p110 β ablation with CAL-101 treatment was not superior to treatment with CAL-101 alone. Similarly, treatment of p110 β -depleted cells with IC488743 prompted a minor decrease pAKT levels compared with the

either p110 β -depletion or IC488743 treatment, suggesting that PIK3CA is responsible for the remaining activity (Figure 2.8. B).

Interestingly, pERK1/2 signaling was reduced in H1650 cells in the p110 β knockdown cells for all conditions (plus or minus CAL-101 or IC488743), but not the other lines (Figure 2.8. A). Densitometric analysis of pERK1/2 showed reduction of signal of nearly 50%, suggesting that one or both isoforms play a role in RAS/MAPK signaling in H1650 cells which may be independent of the phosphorylation of AKT. These data suggest that both the AKT and RAS/MAPK signaling cascades may be linked by multiple independent PI3K isoforms, and functionally these may have kinase independent roles such as a molecular scaffold or adaptor protein.

A.



B.




Figure 2.8. Functional redundancies among class IA isoforms maintain PI3K pathway activation after siRNA-mediated ablation PIK3CB and pharmacological inhibition PIK3CD. (A) A549, PC9, and H1650 cells were transiently-transfected with siRNA specific for p110 β for 24 hr (25nM), then treated with p110 δ inhibitors CAL-101 or IC488743 (1 μ M) for 3 hours before harvesting. Cell lysates were prepared for immunoblotting with indicated antibodies. (B) Densitometric analysis of pAKT (S473) levels normalized to tAKT expression levels.

Treatment with IC488743 or ZSTK474 promotes cell cycle arrest in G₁ but not apoptosis NSCLC cells

Inhibition of p110 β and p110 δ isoforms by genetic and/or pharmacological treatment reduced cell proliferation and inhibited PI3K signaling in A549, PC9, and H1650 NSCLC lines better than isoform-specific inhibitors alone. We sought to understand if reduced proliferation was due to cell cycle arrest or induction of apoptosis, given that the potential consequences on normal and tumor cells.

To identify the cause of reduction in proliferation, we first investigated the cell cycle profile of cells treated with the IC488743 as compared to the pan-isoform inhibitor ZSTK474 at the individual GI₇₅ concentrations for cell lines A549, PC9, and H1650. We chose to assess the compounds at the GI₇₅ because this is the relative concentration where a proliferative phenotype was observed with IC488743. Importantly, when evaluating differences in sensitivity between the two inhibitors, ZSTK474 was on average >50-fold more potent than IC488743 (1.3 μ M vs 73.3 μ M) among the three cell lines. After 24 hr of treatment, both compounds led to significant accumulation in G₁ phase for each cell line with concomitant loss in the S phase compartment (Figure 2.9. A). At 48 hr, we observed a sustained arrest in G₁ in A549 and H1650, however PC9 cells appear to exit G₁ and re-enter into cell cycle. Additionally, at both 24 and 48 hr we detected no change in the % sub-G₁ population suggesting apoptosis was not being induced by inhibitor treatments for all cell lines tested (Figure 2.6. B).

Using identical conditions as outlined above, we also assessed pathway and apoptotic signaling at 24 and 48 hr after treatment with IC488743 and

ZSTK474. As expected, both drugs inhibited phosphorylation of AKT S473 at each time interval. We also observed re-activation of pERK1/2 signaling in the PC9 and H1650 cells (Figure 2.9. C). The increase in pERK signaling in response to treatment was most pronounced in response to ZSTK474 in the EGFR mutant cell lines H1650 and PC9, with only a minor increase observed in KRAS-active A549 cells. We also evaluated cleaved PARP as an apoptotic signaling molecule. We observed no change in cleaved PARP levels with treatment which is consistent with our inability to detect significant changes in sub-G₁ fraction after treatment (Figures 2.9. B and 2.9. C).

To characterize treatment effects on cell cycle progression, we evaluated nuclear and cytosolic levels of cyclin D1 after 48 hr treatments (Figure 2.9. D). Cyclin D1 should be extruded from the nucleus of cycling cells. After 48 hr, cyclin D1 accumulated in the cytosol with treatment of IC488743 or ZSTK474 relative to the controls in A549 and H1650 cells. However, in PC9 cells we observed the presence of nuclear cyclin D1 in drug treated samples, suggesting progression into the cell cycle. Fractionation of the nuclear and cytosolic compartments was confirmed by histone H3 and HSP90 localization.

From these data, only pan-PI3K inhibition or an isoform-selective inhibitor utilized at non-selective concentrations can diminish PI3K/AKT signaling sufficient block proliferation while not inducing apoptosis. However, we note G₁ blockade may be temporary, and taken together with apoptotic failure are likely the result of compensatory mechanisms that increase pERK signaling to escape PI3K/AKT inhibition.




Figure 2.9. IC488743 and ZSTK474 treatment alters G₁ cell cycle progression without inducing apoptosis. (A) Control, IC488743 and ZSTK474 treatment at GI₇₅ concentrations for A549 (IC 65μM and Z 1μM), PC9 (IC 100μM, Z 1.3μM), and H1650 (IC 55μM, Z 1.6μM) cells were assessed for relative cell cycle distributions by propidium iodide (PI) staining of DNA following 24 hr and 48 hr of treatment. Mean percentages of cells in G₀/G₁, S, and G₂/M are

indicated. Error bars represent standard deviation, (n=3) and Student t test showed significant difference (*p<0.05). **(B)** Control, IC488743, and ZSTK474 treated A549, PC9 and H1650 cells were analyzed for % sub-G₁ population indicating apoptosis. Mean percentages of sub-G₁ cells are displayed. Error bars represent standard deviation, (n=3). **(C)** Markers for pathway activation and apoptosis assayed in A549, PC9, and H1650 cells treated at GI₇₅ concentrations of IC488743 (IC) or ZSTK474 (Z) for 24 and 48 hr then harvested for western blot analysis. **(D)** Cells treated for 48 hr with GI₇₅ concentrations of IC488743 or ZSTK474 were subjected nuclear and cytosolic fractionation then western blot analysis to determine the sub cellular localization of G₁ to S-phase regulatory protein cyclin D1.

2.4. DISCUSSION

Lung cancer is a disease characterized by extensive genomic changes that unfortunately lead to millions of deaths worldwide each year because patients do not achieve a sustained response to therapy [247]. Only recently have actionable mutations and mutated signaling pathways been identified and targeted therapeutically [248-251]. Our interests converge on the PI3K/AKT/mTOR signaling axis because it represents one of the most commonly activated pathways in cancer for which few targeted therapies have resulted in clinical use in lung cancer [252].

In lung cancers, mutations have been reported in multiple genes that control PI3K/AKT pathway activation, including EGFR, KRAS, HER3 and BRAF

[49, 159, 186], even though few adenocarcinomas of the lung demonstrate mutations in PIK3CA [163]. Together, these observations make the effector molecules of the PI3K pathway alluring targets for cancer therapy. First generation PI3K inhibitors targeted all class I PI3K isoforms, but were not suitable for clinical use due largely to toxicity and poor bioavailability [253, 254]. Although class IA PI3K isoforms possess similar protein structure, control of expression, and regulation of activity, recent literature reports non-redundant cellular functions that appear to be isoform specific [108, 255-260]. Importantly, to our knowledge, PI3K isoform-specific activities have not been dissected in lung cancers. Therefore, we chose to investigate the intersection of therapeutically-actionable mutations and deregulated activities of the PI3K/AKT signaling cascade in NSCLC cell lines.

We investigated the activity of a panel of PI3K inhibitory compounds in vitro and in cell lines. The IC_{50} values PI3K isoform specificity and selectivity have been previously published and further validated by this laboratory. Using these compounds as tools, we intended to evaluate the activity of each compound for inhibition of growth and/or cell killing in a panel of NSCLC cells and to independently assess the necessity of each PI3K class IA enzymes in NSCLC.

We investigated anti-proliferative responses using a range of drug concentrations overlapping our in vitro estimation of IC_{50} for each isoform. We found that several compounds have anti-proliferative activity against the cell lines tested at micromolar concentrations. Importantly, we found that cell lines

containing mutated PIK3CA were most sensitive to A66. Notably, H460 bears an activating mutation in PIK3CA (E545K) as does H1975 (G188D) which apparently sensitizes the cells to A66 (GI_{50} 8.1 μ M vs 1.59 μ M, respectively). CAL-101 (GS-1101) is a small molecule inhibitor of p110 δ isoform that has been demonstrated to having promising activity against chronic lymphocytic leukemia (CLL) [173, 222, 236]. We found that CAL-101 has similar anti-proliferative activity as the other p110 δ inhibitor tested, IC488743, each demonstrating best activity in H1975 and H460 cell lines. Although CAL-101 and IC488743 elicited similar anti-proliferative profiles they differed most in the EGFR mutant lines PC9 and H1650. It is important to note that the GI_{50} values for even the most sensitive cell lines were well above those estimated IC_{50} values for isoform selectivity, and pharmacologically unachievable. However the data also suggest that at micromolar concentrations we may be achieving dual inhibition of p110 β and p110 δ while sparing p110 α , resulting in diminished cellular proliferation for several cells of multiple genotypes. Having similar potency for individual class IA isoforms as the isoform-selective inhibitors, the pan-PI3K inhibitor ZSTK474 was far more effective at blocking proliferation than any of the isoform-selective inhibitors tested having GI_{50} in nanomolar range for all NSCLC cell lines. The dose-dependent pharmacodynamic experiments largely mirror the proliferation results. Pan-PI3K inhibition with ZSTK474 completely abrogated pAKT signaling at 0.5 μ M and >50% at 0.1 μ M for A549, H1650 and PC9 cell lines (Figure 2.5.). For isoform-selective inhibitors, impaired PI3K/AKT pathway signaling was observed at micromolar concentrations, and elicited an anti-

proliferative response in most cases. Whereas, treatment at concentrations suitable for on target single isoform selectivity had little effect on proliferative signaling with the exception of A66 in PIK3CA active H1975 and possibly H460. A noteworthy counter example was identified in the PTEN-null prostate cancer cell line PC3, where we found selective p110 β inhibition with TGX-221 effective at blocking proliferation and pathway activation relative to p110 α , and p110 δ selective inhibitors (Figure 2.6.). However, among the NSCLC cell lines, TGX-221, CAL-101 and IC488743, to achieve proliferative control these drugs are acting like weak pan-class IA PI3K inhibitors, largely inhibiting only p110 β and p110 δ , and off-target activity on p110 α at higher concentrations. Consistent with this experiment, time-dependent inhibition of PI3K/AKT signaling was achieved with partial off-target activity that had differential effects that were sustained among the NSCLC cell lines. From these observations it is evident that PC9 cells are resistant to targeting p110 β and p110 δ isoforms, whereas H1650 cells are resistant to targeting p110 α .

Together, these data suggest that there may be inherent resistance mechanisms in place in these cells such that isoform-selective inhibition of individual PI3Ks has minimal impact on intrinsic cell proliferative and survival signals.

Interestingly, in the preclinical development of CAL-101, drug concentrations of 5-10 μ M were needed to achieve cytotoxic activity which is at least 1000x more than the predicted IC₅₀ for p110 δ , likely inhibiting both p110 β and p110 γ PI3K isoforms. Furthermore, clinical exposure to CAL-101 is greater

than 2 μ M at lowest doses, suggesting that partial inhibition of other PI3K isoforms such as p110 β may contribute in part to clinical cytotoxic effects observed in patients [242, 243, 261, 262]. Thus, therapeutic resistance to PI3K isoform-specific inhibition might involve one or more of the following mechanisms: compensation by other PI3K enzymes, compensatory signaling from components within PI3K/AKT pathway and/or elements from other oncogenic pathways, or over-expression of efflux transporters.

We chose to investigate the possibility of compensating PI3K enzymes with respect to resistance to the PIK3CD inhibitors, CAL-101 and IC488743, each of which possess a different selectivity profile for PIK3CA, PIK3CB and PIK3CD. Using siRNA-mediated knockdown of p110 β , we tested the activity of CAL-101 and IC488743 in three cell lines each having variable sensitivity to either drug. From this experiment, it seems likely that ablation of two of the three enzymes of interest (PI3KA/B/D) is necessary to eliminate the majority of the pAKT activity, thought to mediate cell growth and survival.

Given that inhibition of multiple PI3K enzymes results in reduced proliferation, we also investigated the mechanism by which proliferation is halted in the presence of IC488743 and ZSTK474. The concentrations needed to achieve GI₇₅ were significantly lower for the pan-PI3K inhibitor (1 - 1.6 μ M) as compared to IC488743 (55 - 100 μ M), further suggesting that pan-isoform blockade may be therapeutically necessary to negate compensatory PI3K signaling from other class IA isoforms that allow for continued proliferation. Our results indicate that both inhibitors impaired PI3K/AKT pathway signaling leading

to G₁ cell cycle arrest, which corresponded with increased cytosolic sequestration of cyclin D1. Despite having potent effects on proliferation, there was no observable induction of apoptosis for either drug suggesting that targeted inhibition of only the PI3K pathway is insufficient to induce apoptosis in NSCLC cells bearing similar genetic aberrations. In line with this, we observed a reciprocal increase in pERK after treatment with IC488743 and ZSTK474, indicating these cells may be exploiting the extensive pathway cross-talk and feedback mechanisms between PI3K/AKT and RAS/MAPK pathways that allow for cell cycle re-entry and escape from apoptosis. Interestingly, this increase in pERK is not observed in our early 3 hr concentration responses to ZSTK474 treatment at similar concentrations. However, others have shown time dependent feedback activation in response to PI3K inhibition often occur through FOX3A-mediated transcriptional upregulation of ERBB family receptors such as HER2 and HER3 leading to increased pERK signaling [263].

2.5 CONCLUSIONS

In summary, we hypothesized that isoform-selective inhibition of PI3K class IA enzymes was a rational choice for lung cancer patient therapy. Importantly, we found that PIK3CA mutated cells responded to p110 α inhibition. Inhibition of both p110 β/δ was more effective than inhibition of individual p110 β and p110 δ isoforms alone, however none of these appear to have clinical relevancy among the NSCLC tumor subtypes we tested. Overall, our findings provide evidence that redundancy among class IA isoforms contributes to drug

resistance, and that pan-class I PI3K inhibitors may hold greater therapeutic promise. Given the challenges for identifying effective treatment of lung cancer and the need to overcome various forms of therapeutic resistance, the most effective use of PI3K inhibitors may ultimately be in combination with other targeted or cytotoxic therapies.

CHAPTER 3

3.1.1 OVERVIEW

The deregulated activation the PI3K pathway is a hallmark in human cancer, thus making PI3K a logical target for therapeutic exploitation. New inhibitors of the PI3K pathway having improved potency and fewer side effects compared to first generation drugs [201]. Of these, there has been increasing interest those inhibitors having selectivity for individual PI3K isoforms. Our lab as well as others report that class IA PI3K isoforms have both dependent and redundant activities that is partially determined by the genetic context [231].

Accrued knowledge from these studies suggests that p110 α responds preferentially to activated receptor tyrosine kinases (TKIs) whereas, p110 β is the dominant isoform in tumors having phosphatase and tensin homolog (PTEN) loss-of-function mutations [99, 173, 174, 219-221]. Our studies outlined in Chapter 2 characterized and compared the activity of class IA isoform-selective inhibitors with that of a pan-class I PI3K inhibitor and found that likely compensatory signaling among the isoforms reduced overall sensitivity to the inhibitors despite genetic drivers, thus limiting the therapeutic promise for these drugs.

The implementation of molecular-based targeted therapies should not be a “one size fits all” approach. The mutational heterogeneity of lung cancers have made difficult single-agent targeted therapeutics as compared to traditional chemotherapies. The inhibition of a single target or pathway essential for tumor proliferation is likely a temporary effect and does not produce sustained growth

arrest. Prominent examples are found for inhibitors targeting EGFR, estrogen receptor (ER), and androgen receptor (AR) [38, 264, 265]. The complexity of tumor signaling networks, particularly in advanced tumors, which often have multiple molecular aberrations and context-specific pathway crosstalk, that ultimately prevent or circumvent the therapeutic blockade. Therefore, adopting a strategy to achieve robust lasting therapeutic control of a cancer may require rational combinations of targeted anti-cancer agents. The use of combined targeted therapies may serve to impair compensatory mechanisms and overcome resistance to therapy, and will require a better understanding of the complex signaling in context with molecular drivers of disease to identify valuable drug combinations.

3.1.2 INTRODUCTION

In adenocarcinomas of the lung, activating mutations in EGFR and KRAS comprise approximately 40% of genetic alterations. EML4ALK translocations, loss/gain of function of BRAF, PIK3CA, AKT1 and MEK comprise another 10-15% of cases [36]. A unifying theme among all of these alterations is that they interact either directly or indirectly with the PI3K pathway signaling. Importantly, targeted inhibition of the epidermal growth factor receptor (EGFR) can be an important target for treatment of advanced non-small cell lung cancer (NSCLC) [249, 266]. These drugs are safe, maintain a good toxicity profile and are well tolerated at high doses [267]. Small molecule inhibitors that block the tyrosine kinase domain of EGFR have been approved for treatment of locally advanced or

metastatic NSCLC as a second- or third-line therapy [266]. Although, EGFR-TKIs are approved as second-line treatment for advanced NSCLC, nearly 50% of patients are unable to obtain second-line treatment (non-platinum single-agent cytotoxic) due to the rapid decline of their clinical condition [268]. This represents key clinical end-point, especially for patients with aggressive tumors, as they need to be treated with drugs that in a second-line setting that demonstrate prolonged survival and preserve quality of life [269]. Divergent clinical responses to EGFR-TKI treatments have been associated with EGFR mutations and KRAS mutations. Patients harboring EGFR mutations in exons 19 and 21 are sensitive to TKI, whereas presence of PTEN or KRAS mutations define innate resistance to TKI therapy. However, most who initially benefit from EGFR-TKI treatment eventually experience tumor regrowth after 12 months of progression free disease [270]. Approximately 75% of resistance on therapy are attributable to either the T790M mutations of EGFR or the amplification of MET oncogene. Each of these can lead to reactivation of PI3K survival signaling [43-45].

Unlike EGFR mutant tumors, there are no current targeted therapeutic options for KRAS-active cancers. Activating mutations in KRAS result in defective GTPase activity leading to constitutive activation of multiple pathways responsible for cell growth and survival such as PI3K/AKT and RAF/MEK/ERK pathways [271]. Efforts to directly target KRAS have proven unsuccessful to date. However, other routes currently being investigated are to target the downstream effectors of RAS such as RAF, MEK, and PI3K. Although KRAS-active cancers are generally thought to be unresponsive to EGFR-TKI therapy,

there is also a more complex model to consider. Others have demonstrated that genotypically heterogeneous subpopulations of tumors are common [272]. Assuming the TKI-sensitive EGFR mutant subpopulations are killed by the targeted therapy, the growth and maintenance of the remaining non-EGFR mutant cells are unaffected manifesting as therapeutic resistance. In the SATURN trial, a large phase III trial having 889 randomized patients having not progressed after first-line chemotherapy, received erlotinib or placebo as a maintenance treatment [273]. Of these, 493 (55.4%) were analyzed for KRAS mutations. The study found that, irrespective of KRAS status, patients treated with erlotinib had longer progression free survival (PFS), with a modest but not statistically significant improvement in the KRAS mutant population. Meaning that in patients harboring KRAS mutations that do not respond to EGFR-TKIs, a minimal survival effect may occur. Although several studies do identify a higher prevalence of clinical responders among KRAS wild-type as compared to KRAS mutant, diagnostic KRAS testing is not recommended for precluding an EGFR-TKI therapy to any NSCLC patients [274-276]. One must also consider the possibility that wild-type EGFR may still play a role in modulating growth survival signaling in KRAS-active cancers.

As summarized above, KRAS-active cancers and other therapy resistant subpopulations may receive some, albeit minor clinical benefit from targeted EGFR therapy overall. Consequently, any undiagnosed mutant tumor subpopulations harboring PTEN or KRAS mutations may negatively impact tumor responses to single-agent EGFR directed therapies leading to tumor regrowth.

Studies have shown tumor subpopulations harboring KRAS mutations in lung and colon cancers to persist at higher levels relative to normal tissue, however remaining undetectable by standard DNA sequencing techniques [277, 278]. Furthermore, PTEN and KRAS mutation status often differ between primary and metastatic tumors [279, 280]. This knowledge provides rationale for combining therapies that impair oncogenic pathways deregulated by PTEN and KRAS mutations (PI3K inhibitor), with those that inhibit EGFR signaling (EGFR-TKI).

Therefore, we propose an accelerated therapeutic strategy intended to prolong survival of those with advanced NSCLC after failure to progress on first-line chemotherapy by treating with EGFR-TKI in combination with a pan-PI3K inhibitor as maintenance therapy subsequent to receiving first-line chemotherapy. We hypothesize that the combined treatment with an EGFR-TKI and pan-PI3K inhibitor will have clinical value, interacting synergistically to sensitize NSCLC cancers innately resistant to EGFR targeted therapy. Our study found that despite being inherently resistant to EGFR-TKI inhibitors, tumors harboring KRAS mutations or defective PTEN are sensitized to EGFR therapy when combined with PI3K inhibition to arrest cell proliferation.

3.2. METHODS

Cell Lines and Culture Conditions

Human NSCLC cell lines obtained from American Type Culture Collection were A549, H460, and H1650. The lines were frozen at low passage for future use and subsequently were confirmed by STR testing (Bio-synthesis Inc,

Lewisville, TX.). All cell lines were propagated as monolayer cultures at 37°C in 5% CO₂ using growth media containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS), glucose, sodium pyruvate, HEPES buffer and penicillin-streptomycin (Life Technologies, Grand Island, NY).

Reagents

The inhibitors erlotinib (EGFR-TKI) and ZSTK474 (pan-PI3K) were purchased from Selleckchem (Houston, TX). All inhibitors were dissolved in DMSO (Sigma Aldrich Corp, St. Louis, MO; BP231-100) to a stock concentration of 10mM, stored at -20C, and diluted to indicated final concentration in RPMI 1640 containing 1% FBS at time of use.

Cell Proliferation Assessment

The growth inhibitory activity of each compound was tested on cells using the Alamar Blue viability assay [237, 238]. Cells were plated at 2×10^3 cells/well in 96-well cell culture plate (USA Scientific, Ocala, FL; CC7682-7596). After adherence, cells were treated 24 hr later with treated with indicated combinations of erlotinib and ZSTK474 for 72 hr diluted in RPMI 1640 containing 1% serum. Dose-response curves and GI₅₀ values were calculated using Graphpad Prism software.

Statistical analyses

Cell proliferation assays were completed three times with a minimum of 2 replicates per experiment. The technical replicate values were averaged for the three experiments and plotted, mean \pm standard deviation (SD). CompuSyn software was used to evaluate drug combination median effects and combination indices (CI). CompuSyn algorithm simulating drug interactions utilize Chou-Talalay method, where additive effect (CI = 1), synergism (CI > 1), and antagonism (CI < 1) [281].

3.3. RESULTS

Combined EGFR-TKI and pan-PI3K inhibitor act synergistically to impair proliferation of KRAS-active NSCLC

We investigated the growth inhibitory activity of the EGFR-TKI, erlotinib, and the pan-PI3K inhibitor, ZSTK474, as measured in the NSCLC cell lines A549 and H460 by Alamar Blue assay (Figure 3.1.) We found that both A549 and H460 were similarly insensitive to single-agent exposure to erlotinib, reaching 50% growth inhibition at concentrations >3 μ M. The pan-PI3K inhibitor was markedly more potent, achieving half maximal growth inhibitory concentration in the nanomolar range.

Studies were then performed to determine the effect of combined EGFR-TKI and pan-PI3K inhibitor treatment on cell proliferation over 72 hr. Each inhibitor combination was tested at concentrations spanning GI₅₀ values. We found that the combinations of erlotinib and ZSTK474 were more growth

inhibitory than either compound alone. Although similar, H460 cells demonstrated greater growth inhibition in response to the drug combinations. Growth inhibition was evaluated by median effect analysis (CompuSyn, Memorial Sloan-Kettering Cancer Center and MIT) to determine if the improved growth inhibitory activity of the combinations was additive or synergistic (Figure 3.2.). Combinations were synergistic at 1:1, 1:10, and 1:100 ratios (ZSTK474:erlotinib), but antagonistic effects were evident at 10:1 and 100:1 ratios (ZSTK474:erlotinib) (Table 3.1.). Overall, while a synergistic interaction was observed with pan-PI3K and EGFR-TKI inhibitors that impaired cell proliferation, we identified modest cytotoxic effect in the H460 cell line occurring at highest tandem drug concentrations.

Synergistic combinations of EGFR-TKI and pan-PI3K inhibitor block proliferation in EGFR mutant/PTEN-null NSCLC

The proliferative effects of erlotinib and ZSTK474 drug combinations were evaluated in the NSCLC cell line H1650 by Alamar Blue assay (Figure 3.3. A) H1650 cells were also found to be insensitive to single-agent erlotinib treatment, whereas the single-agent pan-PI3K inhibitor was more effective at impairing proliferation after 72 hr exposure comparatively. Median effect analysis was calculated for each drug combination in order to assess inhibitory drug interactions (Figure 3.3. B). Our results for H1650 were similar to those found for A549 and H460, where synergistic interactions for ZSTK474:erlotinib ratios occurred at 1:1, 1:10 and 1:100, and antagonism in combinations where ZSTK474 concentrations exceeded the erlotinib concentrations (i.e. at ratios of

10:1, 100:1). Interestingly, at highest concentrations of erlotinib (30 and 3 μ M) we see identical responses to ZSTK474 combinations, each resulting in the complete blockade of proliferation and minor cytotoxicity.




Figure 3.1. Growth inhibition in KRAS mutant NSCLC induced by EGFR-TKI, erlotinib (ERL), and the pan-PI3K inhibitor, ZSTK474, alone and in combination. A549 and H460 cells were treated with indicated concentrations of each inhibitor, as single-agent, or in combination. Combination data are presented as individual curves at fixed erlotinib concentrations (0.03 – 30µM) plotted against increasing ZSTK474 concentrations (0.03 – 30µM). Points represent mean of three independent experiments \pm S.D., and lines were fitted using non-linear regression analysis.





Figure 3.2. Interaction of EGFR-TKI and pan-PI3K inhibitors in KRAS mutant NSCLC. Median effect analysis was performed by CompuSyn software to study the interaction between the inhibitor combinations at the concentrations indicated in Figure 3.1. and Table 3.1. Points represent the mean of three independent experiments. Dotted lines mark range of interaction classification.

A.



B.




Figure 3.3. Proliferative responses and inhibitor interactions to combination EGFR-TKI and pan-PI3K inhibition in EGFR mutant, PTEN-null NSCLC. (A) Combination effects on proliferation in EGFR mutant NSCLC. Data presented as previously described in Figure 3.1. Points represent mean of three independent experiments \pm S.D., and lines were fitted using non-linear regression analysis. **(B)** Interaction of EGFR-TKI and pan-PI3K in EGFR mutant NSCLC. Data are presented as previously described.

A549		ERL [μM]			
		30	3	0.3	0.03
ZSTK474 [μM]	30	0.62	1.58	1.99	2.08
	3	0.13	0.22	0.27	0.31
	0.3	0.11	0.15	0.28	0.44
	0.03	0.17	0.25	0.42	0.97

H460		ERL [μM]			
		30	3	0.3	0.03
ZSTK474 [μM]	30	0.52	1.22	1.65	1.84
	3	0.05	0.1	0.18	0.18
	0.3	0.02	0.08	0.2	0.211
	0.03	0.03	0.06	0.79	0.61

H1650		ERL [μM]			
		30	3	0.3	0.03
ZSTK474 [μM]	30	0.4	0.99	3.38	6.74
	3	0.18	0.27	1.06	3.09
	0.3	0.06	0.04	0.21	1.28
	0.03	0.03	0.01	0.03	0.18

Table 3.1. Summary of drug combinations with corresponding combination indices. Table summarizes calculated combination index value (CI) indicating individual concentrations of erlotinib (ERL) and ZSTK474 used in combination.

3.5. DISCUSSION

The intersection of signaling pathways involved in cancer has only recently been exploited for therapeutic gain. The PI3K/AKT pathway and RAS/MAPK pathway both signal downstream of receptor tyrosine kinases, and are considered central mediators of oncogenic signaling in solid tumors [107]. Numerous targeted small molecule inhibitors are currently under development targeting various elements of these cascades such as EGFR, PI3K, AKT, RAF and MEK [103, 214]. However, tumors often have molecular aberrations affecting multiple signaling pathways making single-agent inhibitors ineffective. Both pre-clinical evidence and early phase clinical trials suggest that combination therapy may be a more effective strategy as compared to single-agent treatments. Our experience with infectious diseases, such as HIV and tuberculosis, underscores the importance and success of drug combinations as therapeutic strategy [282] .

In the current study, we investigated the combined pharmacological inhibition of EGFR and PI3K in NSCLC cell lines resistant to EGFR-TKI therapy. Cells harboring KRAS activating mutations rarely coexist with mutations affecting EGFR, and are largely considered de-novo resistant to single-agent EGFR-TKI therapy because RAS lies downstream of EGFR, thus oncogenic signaling through PI3K/AKT and MAPK pathways can persist despite EGFR activation [223]. H1650 cells are found to contain both mutant EGFR (DelE746-A750) and PTEN deletion. Previous reports as well as observations in our lab have observed that cells harboring loss-of-function PTEN mutations are resistant to

EGFR inhibitors [172]. These studies demonstrate that in cells that are EGFR dependent, loss of PTEN may partially uncouple constitutive mutant EGFR signaling from downstream pathways PI3K/AKT and RAS/MAPK, thereby contributing to EGFR-TKI resistance. Together, these support targeting the PI3K pathway may be effective strategy to impede proliferation in EGFR inhibitor resistant tumors.

We have previously shown that all of the NSCLC cell lines (A549, H460, H1650) tested were sensitive to the single-agent pan-PI3K inhibitor ZSTK474. For KRAS-active A549 and H460, GI_{50} values 0.33 μ M and 0.15 μ M, and EGFR/PTEN mutant H1650 had GI_{50} at 0.69 μ M (Figure 2.3., Table 2.2.). Anti-proliferative responses correlated with pharmacodynamic signaling as indicated by complete loss of pAKT signaling (Figure 2.5.). However, single-agent pan-PI3K treatment did not induce apoptosis (Figure 2.9.). These data also suggest that oncogenic signaling through PI3K/AKT may not be limited to any specific cancer genotype and suggests that constitutive pathway activation may be limiting efficacy of PI3K inhibitors. We found that most EGFR-TKI and pan-PI3K inhibitor combinations tested in this study demonstrated marked synergistic growth inhibitory activity in all cell lines tested (Table 3.1.). These observations support and extend previous in vitro data demonstrating that PI3K inhibitors used in combination with cytotoxic agents, as well as anti-EGFR and MEK inhibitors have improved anti-tumor activity relative to single-agent treatments [159, 283-285].

When comparing dose response curves of drug combinations, we note distinct trend differences between the KRAS mutant and EGFR mutant NSCLC cell lines (Figure 3.1. and Figure 3.3.). Interestingly, among the KRAS mutant lines A549 are wild-type for PIK3CA, whereas H460 harbors (E545K) PIK3CA activating mutation, we do see an improved synergistic effect and cytotoxicity at higher drug combinations in H460 comparatively. Both KRAS mutant cell lines fail to respond to increasing erlotinib doses, thus reduction in proliferation is largely in response to PI3K inhibition. The opposite is observed in EGFR mutant H1650 cells. Proliferative capacity appears to be a function of EGFR-TKI concentration, not the PI3K inhibitor (Figure 3.3.).

Whereas all combinations were growth inhibitory, we observed best drug synergism at ZSTK474: ERL drug ratios where 1:10, 1:100 1:1000 (Table 3.1.), suggesting lower doses of PI3K inhibitor combined with erlotinib at concentrations at or above GI_{50} may be therapeutically most effective. Whereas, the combined treatments at reverse ratio had an antagonistic effect on cell proliferation (Table 3.1. and Figure 3.2.).

To date, targeting tumors with PTEN alterations or KRAS-active cancers with PI3K inhibitors has yielded mixed results. Neither of the two most studied pan-PI3K inhibitors, BKM-120 or GDC-0941, have demonstrated any preferential activity in vitro in PTEN-null cells [286, 287]. No responses to these drugs have been observed in patients bearing PTEN defective tumors in single-agent phase I trials [288]. Likewise, targeting KRAS mutant cancers with single-agent PI3K inhibitors have yet to demonstrate benefit [289]. A recent study identified tumors

having PIK3CA alterations or HER2 amplification were associated with sensitivity relative to those harboring PTEN or BRAF mutations, or tumors with concurrent PIK3CA and KRAS mutations which were all associated with resistance to the p110 α selective inhibitor BYL719 [246]. For this reason, a potential strategy for treatment for KRAS-active cancers is largely focused on utilizing PI3K inhibitors in combination with MEK kinase inhibitors.

Additionally, the presence of KRAS mutations has also been proposed to be a negative predictor for response to anti-EGFR therapies in lung cancer patients [271, 276, 290]. This however, is disputed as evidenced by the phase III SATURN trial among others, whereby KRAS mutant patients had improved survival and no negative effects from single-agent EGFR-TKI therapy [273]. Inherent resistance to EGFR therapy is primarily associated with the absence of drug sensitizing mutations in EGFR, and to a lesser extent presence of other particular oncogenic molecules. Thus, the predictive value associated with EGFR mutational status for selection of patients for EGFR-TKI therapy outweighs KRAS status as a potential negative predictor of clinical benefit [274]. Along with the added difficulty of identifying minor tumor subpopulations, and genetic variability among primary and metastatic sites, clinically there may be rationale for combining EGFR-TKI with a PI3K inhibitor as a maintenance treatment regardless of tumor genotype.

3.5 CONCLUSIONS

From this investigation, we find that concurrent EGFR-TKI and pan-PI3K inhibition may be an effective therapeutic strategy sensitize tumors innately resistant to EGFR-TKI therapy. We show that combinations act synergistically to sensitize KRAS mutant and EGFR/PTEN mutant NSCLC human tumor cells lines that improve cytostatic responses. These effects also suggest that therapeutic resistance to PI3K kinase inhibitors may arise from upstream signaling through both wild-type and mutant EGFR. These preclinical data may offer new strategies for clinical progress accelerating ever more efficient and tolerable cancer therapies. Future study is needed to assess most effective scheduling of EGFR and PI3K inhibitors in order to better characterize and maximize observed synergistic effect on proliferation. This is particularly important because antagonism was observed in combinations at higher concentrations of PI3K inhibitor. Finally, additional controls representing normal lung epithelial cells should be included to provide early insight into issues of toxicity.

CHAPTER 4

4.1. SUMMARY OF RESULTS

The overarching hypothesis of this dissertation was that PI3K represents a clinically valuable molecular target for treatment of NSCLC.

The first hypothesis, outlined in Chapter 2, was tested using NSCLC cell line models to characterize the activity of isoform-selective pharmacological and genetic inhibitors of PI3K as compared to pan-class I PI3K inhibition. We identified that all class IA PI3K isoforms were expressed, albeit at differing levels among the cell lines tested, and having no correlation to known mutational status. We demonstrate that isoform-selective inhibitors of PI3K were found to be capable of inhibiting PI3K/AKT signaling necessary for proliferation in some genetic contexts or cell types such as mutant PIK3CA (with A66) or in PTEN deficient tumors of the prostate (with TGX-221). However, relative to pan-PI3K inhibition, all of NSCLC cell lines were resistant to isoform-selective PI3K inhibition, as reflected by micromolar GI₅₀ values, and the inability to fully abrogate PI3K signaling. These results suggest that compensation among individual isoforms limit efficacy of isoform-selective inhibitors, and the presence of concurrent genetic aberrations further diminish any anti-tumor activity of PI3K inhibitors. Evidence for isoform compensation was further confirmed through studies using siRNA-mediated knockdown of p110 β . Whereby the genetic loss of the p110 β isoform alone had minor effects on PI3K/AKT signaling, and further signal attenuation was only partially achieved by addition of p110 δ inhibitors. Finally, we identified that treatment with isoform-selective inhibitors and pan-PI3K

inhibitors are not cytotoxic, only producing a temporary cytostatic effect through G₁ arrest. This study highlights a fundamental dilemma for implementing isoform-selective inhibitors of PI3K, given that redundancy among the PI3K isoforms limit their effectiveness despite isoform expression levels and genetic context.

In Chapter 3, given that isoform-selective inhibition of PI3K in NSCLC was ineffective relative to pan-PI3K inhibition, we investigated the utility of combined pan-PI3K and EGFR inhibition to overcome resistance associated with single pathway inhibition. We hypothesized that simultaneously drugging the upstream surface receptor EGFR and PI3K may achieve more complete pathway control leading to improved anti-proliferative responses. The combination of pan-PI3K inhibitor, ZSTK474, and EGFR-TKI, erlotinib, resulted in synergistic blockade of proliferation in EGFR therapy resistant NSCLC cell lines. Thus, combined blockade of PI3K and EGFR may represent an effective therapeutic strategy in both wild-type and EGFR activated tumors, and may enhance anti-proliferative responses in tumors harboring concurrent mutations affecting PIK3CA or PTEN.

4.2. CONTRIBUTION TO THE FIELD

This work contributes to the fundamental understanding of the PI3K signaling cascade, and its role as an oncogenic pathway in NSCLC. The frequent activation of the PI3K/AKT pathway in cancer, and its critical role in tumor proliferation and survival make it a desirable target for drug discovery efforts. However, the recent boom in PI3K inhibitor development and

diversification has made difficult direct comparisons between drugs, models, and strategies for ideal clinical and genomic contexts. Our work addresses this important facet of targeted therapy, that being the ability for a drug (i.e. isoform-selective or pan-PI3K inhibitor) to achieve sufficiently complete pathway inhibition, and if that can translate into anti-tumor activity at tolerable patient doses. Through the characterization of in vitro activities of isoform-selective inhibitors we identified contexts whereby targeting particular isoforms may be clinically relevant and achievable, however isoform-selective inhibitors by design have poor selectivity for particular isoforms and consequently lack potency needed to impede all PI3K signaling. Expanding upon this, our work goes on to describe an inherent mechanism of resistance to PI3K inhibitors resulting from compensatory class IA isoform signaling. Taken further, PI3K inhibitors have demonstrated promise when treated in combination with other therapies. In our study, we sought to explore the potential of combining an EGFR-TKI with a pan-PI3K inhibitor for treatment of EGFR therapy resistant NSCLC. As previously discussed, tumors harboring EGFR kinase domain mutations demonstrate favorable responses to EGFR-TKI. Because H1650 are EGFR (DelE746-A750) and PTEN deficient, targeting EGFR and PI3K in combination is a rational approach to overcoming PTEN mediated resistance to EGFR-TKI therapy. This combination strategy was also effective at blocking proliferation of KRAS-active cancers, which currently have no therapeutic options. There are a number of ways a cancer being wild-type EGFR and KRAS-active might be sensitized to combined EGFR-TKI and PI3K therapy. First being the interconnected nature of

EGFR signaling downstream to PI3K/AKT and RAS/MAPK pathways.

Pharmacological blockade of EGFR likely reduces the overall mitogenic signaling downstream of EGFR receptors. Likewise, KRAS-active cancers signal downstream to both PI3K/AKT and MAPK pathways. Simultaneous inhibition of EGFR and PI3K, may reduce the overall oncogenic signaling downstream to both PI3K/AKT and RAS/MAPK pathways meanwhile the pan-PI3K inhibitor is able to fully block PI3K signaling. The interconnected feedback activation or repression between these two pathways remains an active area of research and may also contribute to the synergistic interaction. Finally, the PI3K blockade and potential reduction in RAS/MAPK signaling may negatively affect expression of ERBB family ligands, which may act to further reduce the overall contribution to proliferation by ERBB receptors. Although continued work must be done in order to identify and dissect the mechanism of this drug combination, we are encouraged by these findings which necessitate further investigation of this drug combination in a mouse xenograft model as a logical next step. Going forward further consideration must also be given to the optimal dosing conditions for each agent to achieve maximal therapeutic control while avoiding any associated toxicity.

4.3. TRANSLATIONAL AND CLINICAL RELEVANCE

The findings in this body of work hold substantial translational and clinical relevance as more PI3K inhibitors enter the clinical setting. A key question this dissertation addresses is whether compounds targeting single PI3K isoforms can

provide significant single-agent efficacy in NSCLC cells that express multiple isoforms, and how those responses compare to those observed with pan-PI3K inhibitors. We know that the PI3K/AKT pathway is important in cancer, and has great potential as a target for therapy. This work is the first to evaluate the individual PI3K isoforms as targets for therapy in genetically diverse NSCLC models.

Ultimately, for successful translation from cell culture models to the clinical implementation of rationally selected of single or combined targeted therapeutics, there must be characterization of pharmacodynamic and pharmacokinetic responses to single- and dual-agent therapy. Our work dissects the preclinical biomarkers for drug activity to assess the pharmacodynamic and kinetic responses to PI3K inhibition to better identify NSCLC subtypes sensitive to these drugs. Through this characterization we identified considerable redundancy among class IA PI3K isoforms for sustaining proliferation and survival. This represents a challenge for development of isoform-selective inhibitors, and calls into question the necessity for even more diversified PI3K inhibitor selectivity profiles. We speculate there may in fact be an advantage to developing a p110 α/β selective inhibitors that target isoforms most highly expressed in solid tumor tissues of origin, and do not target the p110 δ and p110 γ isoforms, which would likely spare immune cells and avoid related toxicity. However, taken together we determined that isoform-selective inhibitors will likely fail in a clinical setting due to incomplete negative regulation of PI3K signaling.

Lastly, substantial evidence suggest single-agent inhibitors are ineffective as anti-cancer agents due to either lack of response or acquired resistance to drug [8,13-16]. Therefore, greater clinical responses may be realized through combinations of PI3K inhibitors with other targeted therapies. There is already emerging clinical support for this approach, for example the promising results combination study using the pan-PI3K inhibitor GDC-0941 with the HER2 directed therapy, trastuzumab, that was found also effective in trastuzumab-resistant cell models [291, 292]. Similarly, combining EGFR and PI3K inhibition could improve sensitivity in EGFR therapy resistant NSCLC. Utilizing two models for innate EGFR therapy resistance; we found concurrent blockade of EGFR and PI3K can synergistically block KRAS mutant NSCLC proliferation. This revelation is particularly important because KRAS driven tumors are the most common single-driver mutations found in advanced NSCLC, and currently there are no therapeutic options for these patients. The EGFR/PI3K inhibitor combination was also found to be effective in EGFR active NSCLC that are resistant to targeted EGFR inhibitors due to the functional loss of PTEN. This model underscores how in advanced cancers having multiple pathway defects, single-agent targeted therapies are ineffective due to uncoupled dependence (“loss of oncogene addiction”) for a single driver such as EGFR. Thus permitting sustained pathway activation and the opportunity for pathway cross-talk. As a result of these studies, we hypothesize an overall initial increase in partial clinical responders to the combination, by sensitizing previously resistant NSCLC subtypes. We also predict that in EGFR-sensitive NSCLC, this combination

could also minimize or reduce the eventual selective pressure for the development and outgrowth of EGFR-TKI resistance by blocking reactivation of PI3K/AKT pathway. Slowing tumor reinitiation even by a single month would represent a significant clinical breakthrough in NSCLC patients having acquired resistance to EGFR therapy.

As summarized above, the translational promise of this combination strategy targeting PI3K and EGFR are manifold. Foremost being those patients who currently have little or no therapeutic options, such as those harboring KRAS-active cancers. Secondly, as compared to front line cytotoxic therapies, the optimized use of orally available targeted inhibitors combination will likely represent a more convenient and tolerable treatment regimen. Finally, for patients receiving benefit from EGFR directed therapy, the addition of a PI3K inhibitor may improve duration of response relative to current single-agent therapy.

4.4. CONCLUSIONS

In conclusion, we were unable to prove our hypothesis that activated PI3K is a good single-agent target for treatment of NSCLC. We find that isoform-selective PI3K inhibitors lack potency relative to pan-PI3K inhibitors due to redundancies among isoform signaling. Although superior to isoform selective inhibitors, treatment with the pan-PI3K inhibitor alone had only temporary cytostatic anti-tumor activity. Importantly, we identified that targeting PI3K in combination with an EGFR inhibitor may offer potential benefit in both KRAS

active, EGFR wild-type, and in EGFR mutant NSCLC. We conclude that the value of PI3K as a therapeutic target will not be realized through monotherapy, but rather when PI3K inhibitors are utilized in combination with other rationally selected targeted agents.

APPENDIX

APPENDIX I: SUPPLEMENTARY FIGURES FOR CHAPTER 2

GI ₅₀ values of PI3K inhibitors for NSCLC cell lines					
GI ₅₀ (μM)	A549	H460	H1975	PC9	H1650
Isoform-selective PI3K inhibitors					
A66	5.2	1.27	2.61	7.55	42.08
TGX-221	>100	30.41	25.93	>100	3.58
CAL-101	16.9	35.94	3.49	3.70	6.04
IC488743	4.2	3.86	7.22	13.23	7.84

Table 2.3. Measurement of cell proliferation in synchronized NSCLC cell lines after PI3K inhibitor treatment. Cell lines A549, PC9, H1650, H1975 and H460 cells were treated with increasing concentrations (0.3 - 30 μM) of isoform specific inhibitors A66, TGX-221, CAL-101 and IC488743. Cell proliferation was determined by trypan blue exclusion assay after 72 hr treatment. Data is representative of 2 independent experiments (n=2). Experimental results were normalized to cells serum starved for 24 hr prior to treatment cells and divided by untreated control to determine (% growth relative to control). Non-linear curve fitting and GI₅₀ values were generated using Graphpad Prism.

REFERENCES

1. Papavramidou, N., T. Papavramidis, and T. Demetriou, *Ancient Greek and Greco-Roman methods in modern surgical treatment of cancer*. *Ann Surg Oncol*, 2010. **17**(3): p. 665-7.
2. *The Emperor of All Maladies: A Biography of Cancer*. Booklist, 2010. **107**(1): p. 25.
3. Hanahan, D. and R.A. Weinberg, *The hallmarks of cancer*. *Cell*, 2000. **100**(1): p. 57-70.
4. Macaluso, M., M.G. Paggi, and A. Giordano, *Genetic and epigenetic alterations as hallmarks of the intricate road to cancer*. *Oncogene*, 2003. **22**(42): p. 6472-8.
5. Vogelstein, B. and K.W. Kinzler, *Cancer genes and the pathways they control*. *Nat Med*, 2004. **10**(8): p. 789-99.
6. Ashworth, A., C.J. Lord, and J.S. Reis-Filho, *Genetic interactions in cancer progression and treatment*. *Cell*, 2011. **145**(1): p. 30-8.
7. Crino, L., et al., *Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. *Ann Oncol*, 2010. **21 Suppl 5**: p. v103-15.
8. Ramalingam, S. and C. Belani, *Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions*. *Oncologist*, 2008. **13 Suppl 1**: p. 5-13.
9. Azzoli, C.G., S. Temin, and G. Giaccone, *2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer*. *J Oncol Pract*, 2012. **8**(1): p. 63-6.
10. Bareschino, M.A., et al., *Treatment of advanced non small cell lung cancer*. *J Thorac Dis*, 2011. **3**(2): p. 122-33.
11. Sun, C.T., et al., *A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer*. *Bratisl Lek Listy*, 2014. **115**(4): p. 233-7.
12. Thatcher, N., et al., *Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)*. *Lancet*, 2005. **366**(9496): p. 1527-37.
13. Florescu, M., et al., *A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21*. *J Thorac Oncol*, 2008. **3**(6): p. 590-8.
14. Alberg, A.J., D.R. Shopland, and K.M. Cummings, *The 2014 Surgeon General's report: commemorating the 50th Anniversary of the 1964 Report of the Advisory Committee to the US Surgeon General and updating the evidence on the health consequences of cigarette smoking*. *Am J Epidemiol*, 2014. **179**(4): p. 403-12.
15. *The Health Consequences of Smoking: 50 Years of Progress: a Report of the Surgeon General*. , U.D.o.H.a.H. Services., Editor. 2014: Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
16. *Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service*. , E. US Department of Health, and Welfare., Editor.:

- Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1964. (Public Health Service Publication No. 1103).
17. Proctor, R.N., *The history of the discovery of the cigarette-lung cancer link: evidentiary traditions, corporate denial, global toll*. *Tob Control*, 2012. **21**(2): p. 87-91.
 18. Jemal, A., et al., *Global cancer statistics*. *CA Cancer J Clin*, 2011. **61**(2): p. 69-90.
 19. Siegel, R., D. Naishadham, and A. Jemal, *Cancer statistics, 2012*. *CA Cancer J Clin*, 2012. **62**(1): p. 10-29.
 20. *Cancer Facts & Figures 2013*. 2013, American Cancer Society: Atlanta.
 21. *Behavioral Risk Factor Surveillance System Prevalence and Trends Data, 2012*, C.f.D.C.a. Prevention, Editor.: Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2013 [accessed 2014 Feb 14].
 22. Hecht, S.S., *Tobacco carcinogens, their biomarkers and tobacco-induced cancer*. *Nat Rev Cancer*, 2003. **3**(10): p. 733-44.
 23. Hecht, S.S., *Tobacco smoke carcinogens and lung cancer*. *J Natl Cancer Inst*, 1999. **91**(14): p. 1194-210.
 24. Alberg, A.J., M.V. Brock, and J.M. Samet, *Epidemiology of lung cancer: looking to the future*. *J Clin Oncol*, 2005. **23**(14): p. 3175-85.
 25. Herbst, R.S., J.V. Heymach, and S.M. Lippman, *Lung cancer*. *N Engl J Med*, 2008. **359**(13): p. 1367-80.
 26. Brambilla, E. and A. Gazdar, *Pathogenesis of lung cancer signalling pathways: roadmap for therapies*. *Eur Respir J*, 2009. **33**(6): p. 1485-97.
 27. Imielinski, M., et al., *Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing*. *Cell*, 2012. **150**(6): p. 1107-20.
 28. Sun, S., J.H. Schiller, and A.F. Gazdar, *Lung cancer in never smokers--a different disease*. *Nat Rev Cancer*, 2007. **7**(10): p. 778-90.
 29. Amos, C.I., W. Xu, and M.R. Spitz, *Is there a genetic basis for lung cancer susceptibility?* *Recent Results Cancer Res*, 1999. **151**: p. 3-12.
 30. Hwang, S.J., et al., *Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk*. *Hum Genet*, 2003. **113**(3): p. 238-43.
 31. Fletcher, O., et al., *Lifetime risks of common cancers among retinoblastoma survivors*. *J Natl Cancer Inst*, 2004. **96**(5): p. 357-63.
 32. Cancer Genome Atlas Research, N., *Comprehensive molecular profiling of lung adenocarcinoma*. *Nature*, 2014. **511**(7511): p. 543-50.
 33. Govindan, R., et al., *Genomic landscape of non-small cell lung cancer in smokers and never-smokers*. *Cell*, 2012. **150**(6): p. 1121-34.
 34. Wistuba, II, et al., *High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints*. *Cancer Res*, 2000. **60**(7): p. 1949-60.
 35. Hollstein, M., et al., *p53 mutations in human cancers*. *Science*, 1991. **253**(5015): p. 49-53.
 36. Soh, J., et al., *Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells*. *PLoS One*, 2009. **4**(10): p. e7464.
 37. Weinstein, I.B. and A. Joe, *Oncogene addiction*. *Cancer Res*, 2008. **68**(9): p. 3077-80; discussion 3080.

38. Hynes, N.E. and H.A. Lane, *ERBB receptors and cancer: the complexity of targeted inhibitors*. Nat Rev Cancer, 2005. **5**(5): p. 341-54.
39. Pedersen, M.W., et al., *Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation*. J Cell Biochem, 2005. **96**(2): p. 412-27.
40. Fujimoto, N., et al., *High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor*. Cancer Res, 2005. **65**(24): p. 11478-85.
41. Cohen, M.H., et al., *FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets*. Oncologist, 2003. **8**(4): p. 303-6.
42. Cohen, M.H., et al., *FDA drug approval summary: erlotinib (Tarceva) tablets*. Oncologist, 2005. **10**(7): p. 461-6.
43. Johnson, J.R., et al., *Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen*. Clin Cancer Res, 2005. **11**(18): p. 6414-21.
44. Mulloy, R., et al., *Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib*. Cancer Res, 2007. **67**(5): p. 2325-30.
45. Gazdar, A.F. and J.D. Minna, *Inhibition of EGFR signaling: all mutations are not created equal*. PLoS Med, 2005. **2**(11): p. e377.
46. Jian, Z., et al., *Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes*. Pathol Int, 2005. **55**(10): p. 619-25.
47. Taron, M., et al., *Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas*. Clin Cancer Res, 2005. **11**(16): p. 5878-85.
48. Riely, G.J., et al., *Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib*. Clin Cancer Res, 2006. **12**(3 Pt 1): p. 839-44.
49. Engelman, J.A. and J. Settleman, *Acquired resistance to tyrosine kinase inhibitors during cancer therapy*. Curr Opin Genet Dev, 2008. **18**(1): p. 73-9.
50. Sharma, S.V., et al., *Epidermal growth factor receptor mutations in lung cancer*. Nat Rev Cancer, 2007. **7**(3): p. 169-81.
51. Yun, C.H., et al., *The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP*. Proc Natl Acad Sci U S A, 2008. **105**(6): p. 2070-5.
52. Bean, J., et al., *MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib*. Proc Natl Acad Sci U S A, 2007. **104**(52): p. 20932-7.
53. Mok, T.S., et al., *Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma*. N Engl J Med, 2009. **361**(10): p. 947-57.
54. Han, S.W., et al., *Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib*. J Clin Oncol, 2005. **23**(11): p. 2493-501.
55. Khosravi-Far, R. and C.J. Der, *The Ras signal transduction pathway*. Cancer Metastasis Rev, 1994. **13**(1): p. 67-89.
56. Johnson, L., et al., *Somatic activation of the K-ras oncogene causes early onset lung cancer in mice*. Nature, 2001. **410**(6832): p. 1111-6.
57. Mills, N.E., et al., *Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma*. Cancer Res, 1995. **55**(7): p. 1444-7.

58. Bourne, H.R., D.A. Sanders, and F. McCormick, *The GTPase superfamily: a conserved switch for diverse cell functions*. Nature, 1990. **348**(6297): p. 125-32.
59. Bos, J.L., *ras oncogenes in human cancer: a review*. Cancer Res, 1989. **49**(17): p. 4682-9.
60. Rubio, I., et al., *Interaction of Ras with phosphoinositide 3-kinase gamma*. Biochem J, 1997. **326 (Pt 3)**: p. 891-5.
61. Moodie, S.A., et al., *Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase*. Science, 1993. **260**(5114): p. 1658-61.
62. Roux, P.P. and J. Blenis, *ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions*. Microbiol Mol Biol Rev, 2004. **68**(2): p. 320-44.
63. Castellano, E. and J. Downward, *Role of RAS in the regulation of PI 3-kinase*. Curr Top Microbiol Immunol, 2010. **346**: p. 143-69.
64. Davies, H., et al., *Somatic mutations of the protein kinase gene family in human lung cancer*. Cancer Res, 2005. **65**(17): p. 7591-5.
65. Riely, G.J., et al., *Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma*. Clin Cancer Res, 2008. **14**(18): p. 5731-4.
66. Tam, I.Y., et al., *Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features*. Clin Cancer Res, 2006. **12**(5): p. 1647-53.
67. Wilhelm, S., et al., *Discovery and development of sorafenib: a multikinase inhibitor for treating cancer*. Nat Rev Drug Discov, 2006. **5**(10): p. 835-44.
68. Yeh, T.C., et al., *Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor*. Clin Cancer Res, 2007. **13**(5): p. 1576-83.
69. Flaherty, K.T., et al., *Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations*. N Engl J Med, 2012. **367**(18): p. 1694-703.
70. Kaplan, D.R., et al., *Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity*. Cell, 1987. **50**(7): p. 1021-9.
71. Vanhaesebroeck, B., et al., *Synthesis and function of 3-phosphorylated inositol lipids*. Annu Rev Biochem, 2001. **70**: p. 535-602.
72. Auger, K.R., et al., *PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells*. Cell, 1989. **57**(1): p. 167-75.
73. Traynor-Kaplan, A.E., et al., *Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils*. J Biol Chem, 1989. **264**(26): p. 15668-73.
74. Ruderman, N.B., et al., *Activation of phosphatidylinositol 3-kinase by insulin*. Proc Natl Acad Sci U S A, 1990. **87**(4): p. 1411-5.
75. Vanhaesebroeck, B., et al., *Phosphoinositide 3-kinases: a conserved family of signal transducers*. Trends Biochem Sci, 1997. **22**(7): p. 267-72.
76. Carpenter, C.L., et al., *Purification and characterization of phosphoinositide 3-kinase from rat liver*. J Biol Chem, 1990. **265**(32): p. 19704-11.
77. Hiles, I.D., et al., *Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit*. Cell, 1992. **70**(3): p. 419-29.
78. Falasca, M. and T. Maffucci, *Role of class II phosphoinositide 3-kinase in cell signalling*. Biochem Soc Trans, 2007. **35**(Pt 2): p. 211-4.
79. Yan, Y. and J.M. Backer, *Regulation of class III (Vps34) PI3Ks*. Biochem Soc Trans, 2007. **35**(Pt 2): p. 239-41.

80. Escobedo, J.A., et al., *cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor*. Cell, 1991. **65**(1): p. 75-82.
81. Inukai, K., et al., *Five isoforms of the phosphatidylinositol 3-kinase regulatory subunit exhibit different associations with receptor tyrosine kinases and their tyrosine phosphorylations*. FEBS Lett, 2001. **490**(1-2): p. 32-8.
82. Engelman, J.A., J. Luo, and L.C. Cantley, *The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism*. Nat Rev Genet, 2006. **7**(8): p. 606-19.
83. Huang, C.H., et al., *The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations*. Science, 2007. **318**(5857): p. 1744-8.
84. Bader, A.G., et al., *Oncogenic PI3K deregulates transcription and translation*. Nat Rev Cancer, 2005. **5**(12): p. 921-9.
85. Zhao, L. and P.K. Vogt, *Class I PI3K in oncogenic cellular transformation*. Oncogene, 2008. **27**(41): p. 5486-96.
86. Zhang, X., et al., *Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism*. Mol Cell, 2011. **41**(5): p. 567-78.
87. Vadas, O., et al., *Structural basis for activation and inhibition of class I phosphoinositide 3-kinases*. Sci Signal, 2011. **4**(195): p. re2.
88. Jura, N., et al., *Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms*. Mol Cell, 2011. **42**(1): p. 9-22.
89. Taylor, S.S. and A.P. Kornev, *Protein kinases: evolution of dynamic regulatory proteins*. Trends Biochem Sci, 2011. **36**(2): p. 65-77.
90. Walker, E.H., et al., *Structural insights into phosphoinositide 3-kinase catalysis and signalling*. Nature, 1999. **402**(6759): p. 313-20.
91. Miller, S., et al., *Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34*. Science, 2010. **327**(5973): p. 1638-42.
92. Lempiainen, H. and T.D. Halazonetis, *Emerging common themes in regulation of PIKKs and PI3Ks*. EMBO J, 2009. **28**(20): p. 3067-73.
93. Kornev, A.P., S.S. Taylor, and L.F. Ten Eyck, *A helix scaffold for the assembly of active protein kinases*. Proc Natl Acad Sci U S A, 2008. **105**(38): p. 14377-82.
94. Cantley, L.C., *The phosphoinositide 3-kinase pathway*. Science, 2002. **296**(5573): p. 1655-1657.
95. Domchek, S.M., et al., *Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide*. Biochemistry, 1992. **31**(41): p. 9865-70.
96. Vivanco, I. and C.L. Sawyers, *The phosphatidylinositol 3-Kinase AKT pathway in human cancer*. Nat Rev Cancer, 2002. **2**(7): p. 489-501.
97. Stephens, L.R., K.T. Hughes, and R.F. Irvine, *Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils*. Nature, 1991. **351**(6321): p. 33-9.
98. Hawkins, P.T., T.R. Jackson, and L.R. Stephens, *Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase*. Nature, 1992. **358**(6382): p. 157-9.
99. Pacold, M.E., et al., *Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma*. Cell, 2000. **103**(6): p. 931-43.
100. Ong, S.H., et al., *Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins*. Proc Natl Acad Sci U S A, 2001. **98**(11): p. 6074-9.

101. Rodriguez-Viciano, P., et al., *Phosphatidylinositol-3-OH kinase as a direct target of Ras*. Nature, 1994. **370**(6490): p. 527-32.
102. Pacold, M.E., et al., *Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma*. Cell, 2000. **103**(6): p. 931-943.
103. Castellano, E. and J. Downward, *RAS Interaction with PI3K: More Than Just Another Effector Pathway*. Genes Cancer, 2011. **2**(3): p. 261-74.
104. Pawson, T., *Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems*. Cell, 2004. **116**(2): p. 191-203.
105. Jimenez, C., et al., *The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras*. Journal of Biological Chemistry, 2002. **277**(44): p. 41556-41562.
106. Dorsam, R.T. and J.S. Gutkind, *G-protein-coupled receptors and cancer*. Nat Rev Cancer, 2007. **7**(2): p. 79-94.
107. Guillermet-Guibert, J., et al., *The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma*. Proc Natl Acad Sci U S A, 2008. **105**(24): p. 8292-7.
108. Murga, C., S. Fukuhara, and J.S. Gutkind, *A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt*. J Biol Chem, 2000. **275**(16): p. 12069-73.
109. Maier, U., A. Babich, and B. Nurnberg, *Roles of non-catalytic subunits in G beta gamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma*. Journal of Biological Chemistry, 1999. **274**(41): p. 29311-29317.
110. Dbouk, H.A., et al., *A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase*. Proc Natl Acad Sci U S A, 2010. **107**(46): p. 19897-902.
111. Lappano, R. and M. Maggiolini, *G protein-coupled receptors: novel targets for drug discovery in cancer*. Nat Rev Drug Discov, 2011. **10**(1): p. 47-60.
112. Daub, H., et al., *Signal characteristics of G protein-transactivated EGF receptor*. Embo Journal, 1997. **16**(23): p. 7032-7044.
113. Bholra, N.E. and J.R. Grandis, *Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer*. Frontiers in Bioscience-Landmark, 2008. **13**: p. 1857-1865.
114. Borrell-Pages, M., et al., *TACE is required for the activation of the EGFR by TGF-alpha in tumors*. EMBO J, 2003. **22**(5): p. 1114-24.
115. Alvarez, B., et al., *Phosphoinositide 3-kinase activation regulates cell division time by coordinated control of cell mass and cell cycle progression rate*. J Biol Chem, 2003. **278**(29): p. 26466-73.
116. Memmott, R.M. and P.A. Dennis, *The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis*. Clin Cancer Res, 2010. **16**(1): p. 4-10.
117. Xu, C.X., et al., *Roles of protein kinase B/Akt in lung cancer*. Front Biosci (Elite Ed), 2010. **2**: p. 1472-84.
118. Guo, Y., J. Du, and D.J. Kwiatkowski, *Molecular dissection of AKT activation in lung cancer cell lines*. Mol Cancer Res, 2013. **11**(3): p. 282-93.
119. Massion, P.P., et al., *Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway*. Cancer Res, 2002. **62**(13): p. 3636-40.
120. Brognard, J., et al., *Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation*. Cancer Res, 2001. **61**(10): p. 3986-97.
121. Haslam, R.J., H.B. Koide, and B.A. Hemmings, *Pleckstrin domain homology*. Nature, 1993. **363**(6427): p. 309-10.

122. Harlan, J.E., et al., *Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate*. Nature, 1994. **371**(6493): p. 168-70.
123. Burgering, B.M. and P.J. Coffey, *Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction*. Nature, 1995. **376**(6541): p. 599-602.
124. Anderson, K.E., et al., *Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B*. Curr Biol, 1998. **8**(12): p. 684-91.
125. Stephens, L., et al., *Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B*. Science, 1998. **279**(5351): p. 710-4.
126. Alessi, D.R., et al., *Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α* . Curr Biol, 1997. **7**(4): p. 261-9.
127. Alessi, D.R., et al., *Mechanism of activation of protein kinase B by insulin and IGF-1*. EMBO J, 1996. **15**(23): p. 6541-51.
128. James, S.R., et al., *Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation*. Biochem J, 1996. **315 (Pt 3)**: p. 709-13.
129. Sarbassov, D.D., et al., *Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex*. Science, 2005. **307**(5712): p. 1098-101.
130. Jones, S.M., et al., *PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1*. Curr Biol, 1999. **9**(10): p. 512-21.
131. Jones, S.M. and A. Kazlauskas, *Growth-factor-dependent mitogenesis requires two distinct phases of signalling*. Nat Cell Biol, 2001. **3**(2): p. 165-72.
132. Kumar, A., M. Marques, and A.C. Carrera, *Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry*. Mol Cell Biol, 2006. **26**(23): p. 9116-25.
133. Alessi, D.R., et al., *Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase*. FEBS Lett, 1996. **399**(3): p. 333-8.
134. Cross, D.A., et al., *Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B*. Nature, 1995. **378**(6559): p. 785-9.
135. Vanhaesebroeck, B., L. Stephens, and P. Hawkins, *PI3K signalling: the path to discovery and understanding*. Nat Rev Mol Cell Biol, 2012. **13**(3): p. 195-203.
136. Ryves, W.J. and A.J. Harwood, *The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle*. Prog Cell Cycle Res, 2003. **5**: p. 489-95.
137. Martinez-Gac, L., et al., *Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead*. Mol Cell Biol, 2004. **24**(5): p. 2181-9.
138. Medema, R.H., et al., *AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1*. Nature, 2000. **404**(6779): p. 782-7.
139. Tee, A.R., et al., *Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb*. Curr Biol, 2003. **13**(15): p. 1259-68.
140. Inoki, K., et al., *Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling*. Genes Dev, 2003. **17**(15): p. 1829-34.
141. Long, X., et al., *Rheb binds and regulates the mTOR kinase*. Curr Biol, 2005. **15**(8): p. 702-13.
142. Wang, L., et al., *PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding*. J Biol Chem, 2007. **282**(27): p. 20036-44.

143. Mayer, C., et al., *mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability*. Genes Dev, 2004. **18**(4): p. 423-34.
144. Mahajan, P.B., *Modulation of transcription of rRNA genes by rapamycin*. Int J Immunopharmacol, 1994. **16**(9): p. 711-21.
145. Hay, N. and N. Sonenberg, *Upstream and downstream of mTOR*. Genes Dev, 2004. **18**(16): p. 1926-45.
146. Foster, K.G. and D.C. Fingar, *Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony*. J Biol Chem, 2010. **285**(19): p. 14071-7.
147. Alessi, D.R., L.R. Pearce, and J.M. Garcia-Martinez, *New insights into mTOR signaling: mTORC2 and beyond*. Sci Signal, 2009. **2**(67): p. pe27.
148. Magnuson, B., B. Ekim, and D.C. Fingar, *Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks*. Biochem J, 2012. **441**(1): p. 1-21.
149. Ma, X.M. and J. Blenis, *Molecular mechanisms of mTOR-mediated translational control*. Nat Rev Mol Cell Biol, 2009. **10**(5): p. 307-18.
150. Oh, W.J. and E. Jacinto, *mTOR complex 2 signaling and functions*. Cell Cycle, 2011. **10**(14): p. 2305-16.
151. Montagne, J., et al., *Drosophila S6 kinase: a regulator of cell size*. Science, 1999. **285**(5436): p. 2126-9.
152. Meyuhas, O., *Physiological roles of ribosomal protein S6: one of its kind*. Int Rev Cell Mol Biol, 2008. **268**: p. 1-37.
153. Ding, L., et al., *Somatic mutations affect key pathways in lung adenocarcinoma*. Nature, 2008. **455**(7216): p. 1069-75.
154. Normanno, N., et al., *Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment*. Endocr Relat Cancer, 2003. **10**(1): p. 1-21.
155. Pao, W. and J. Chmielecki, *Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer*. Nat Rev Cancer, 2010. **10**(11): p. 760-74.
156. Riely, G.J., J. Marks, and W. Pao, *KRAS mutations in non-small cell lung cancer*. Proc Am Thorac Soc, 2009. **6**(2): p. 201-5.
157. Jackman, D.M., et al., *Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials*. Clin Cancer Res, 2009. **15**(16): p. 5267-73.
158. Yun, C.H., et al., *Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity*. Cancer Cell, 2007. **11**(3): p. 217-27.
159. Faber, A.C., et al., *Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition*. Proc Natl Acad Sci U S A, 2009. **106**(46): p. 19503-8.
160. Oxnard, G.R., A. Binder, and P.A. Janne, *New targetable oncogenes in non-small-cell lung cancer*. J Clin Oncol, 2013. **31**(8): p. 1097-104.
161. Samuels, Y., et al., *High frequency of mutations of the PIK3CA gene in human cancers*. Science, 2004. **304**(5670): p. 554.
162. Pao, W. and N. Girard, *New driver mutations in non-small-cell lung cancer*. Lancet Oncol, 2011. **12**(2): p. 175-80.
163. Wang, L., et al., *PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup*. PLoS One, 2014. **9**(2): p. e88291.

164. Janku, F., et al., *PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers*. PLoS One, 2011. **6**(7): p. e22769.
165. Engelman, J.A., et al., *Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer*. J Clin Invest, 2006. **116**(10): p. 2695-706.
166. Carracedo, A. and P.P. Pandolfi, *The PTEN-PI3K pathway: of feedbacks and cross-talks*. Oncogene, 2008. **27**(41): p. 5527-41.
167. Hollander, M.C., G.M. Blumenthal, and P.A. Dennis, *PTEN loss in the continuum of common cancers, rare syndromes and mouse models*. Nat Rev Cancer, 2011. **11**(4): p. 289-301.
168. Song, M.S., L. Salmena, and P.P. Pandolfi, *The functions and regulation of the PTEN tumour suppressor*. Nat Rev Mol Cell Biol, 2012. **13**(5): p. 283-96.
169. Marsit, C.J., et al., *PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration*. Hum Pathol, 2005. **36**(7): p. 768-76.
170. Soria, J.C., et al., *Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation*. Clin Cancer Res, 2002. **8**(5): p. 1178-84.
171. Tang, J.M., et al., *Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis*. Lung Cancer, 2006. **51**(2): p. 181-91.
172. Sos, M.L., et al., *PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR*. Cancer Res, 2009. **69**(8): p. 3256-61.
173. Chantry, D., et al., *p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes*. J Biol Chem, 1997. **272**(31): p. 19236-41.
174. Gao, P., et al., *Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN*. Blood, 2005. **106**(8): p. 2619-26.
175. Bi, L., et al., *Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase*. Mamm Genome, 2002. **13**(3): p. 169-72.
176. Bi, L., et al., *Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase*. J Biol Chem, 1999. **274**(16): p. 10963-8.
177. Bachman, K.E., et al., *The PIK3CA gene is mutated with high frequency in human breast cancers*. Cancer Biol Ther, 2004. **3**(8): p. 772-5.
178. Stemke-Hale, K., et al., *An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer*. Cancer Res, 2008. **68**(15): p. 6084-91.
179. Liu, W., et al., *PTEN/MMAC1 mutations and EGFR amplification in glioblastomas*. Cancer Res, 1997. **57**(23): p. 5254-7.
180. Li, J., et al., *PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer*. Science, 1997. **275**(5308): p. 1943-7.
181. Wee, S., et al., *PTEN-deficient cancers depend on PIK3CB*. Proc Natl Acad Sci U S A, 2008. **105**(35): p. 13057-62.
182. Jia, S., et al., *Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis*. Nature, 2008. **454**(7205): p. 776-9.
183. Hill, K.M., et al., *The role of PI 3-kinase p110beta in AKT signaling, cell survival, and proliferation in human prostate cancer cells*. Prostate, 2010. **70**(7): p. 755-64.

184. Saal, L.H., et al., *PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma*. *Cancer Res*, 2005. **65**(7): p. 2554-9.
185. Abubaker, J., et al., *PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma*. *Leukemia*, 2007. **21**(11): p. 2368-70.
186. Yamamoto, H., et al., *PIK3CA mutations and copy number gains in human lung cancers*. *Cancer Res*, 2008. **68**(17): p. 6913-21.
187. Oda, K., et al., *PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation*. *Cancer Res*, 2008. **68**(19): p. 8127-36.
188. Zhao, L. and P.K. Vogt, *Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms*. *Proc Natl Acad Sci U S A*, 2008. **105**(7): p. 2652-7.
189. Yu, J., et al., *Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit*. *Mol Cell Biol*, 1998. **18**(3): p. 1379-87.
190. Carson, J.D., et al., *Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase*. *Biochem J*, 2008. **409**(2): p. 519-24.
191. Chakrabarty, A., et al., *H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3*. *Oncogene*, 2010. **29**(37): p. 5193-203.
192. Mandelker, D., et al., *A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane*. *Proc Natl Acad Sci U S A*, 2009. **106**(40): p. 16996-7001.
193. Zhao, L. and P.K. Vogt, *Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (p13K): differential interactions with the regulatory subunit p85 and with RAS*. *Cell Cycle*, 2010. **9**(3): p. 596-600.
194. Kang, S., et al., *Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase*. *Proc Natl Acad Sci U S A*, 2006. **103**(5): p. 1289-94.
195. Ciruolo, E., et al., *Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development*. *Sci Signal*, 2008. **1**(36): p. ra3.
196. Maier, U., A. Babich, and B. Nurnberg, *Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma*. *J Biol Chem*, 1999. **274**(41): p. 29311-7.
197. Powis, G., et al., *Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase*. *Cancer Res*, 1994. **54**(9): p. 2419-23.
198. Vlahos, C.J., et al., *A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)*. *J Biol Chem*, 1994. **269**(7): p. 5241-8.
199. Gharbi, S.I., et al., *Exploring the specificity of the PI3K family inhibitor LY294002*. *Biochem J*, 2007. **404**(1): p. 15-21.
200. Knight, Z.A., et al., *Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold*. *Bioorg Med Chem*, 2004. **12**(17): p. 4749-59.
201. Workman, P., et al., *Drugging the PI3 kinome: from chemical tools to drugs in the clinic*. *Cancer Res*, 2010. **70**(6): p. 2146-57.
202. Serra, V., et al., *NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations*. *Cancer Res*, 2008. **68**(19): p. 8022-30.

203. O'Reilly, K.E., et al., *mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt*. *Cancer Res*, 2006. **66**(3): p. 1500-8.
204. Harrington, L.S., et al., *The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins*. *J Cell Biol*, 2004. **166**(2): p. 213-23.
205. Yeh, J.E., P.A. Toniolo, and D.A. Frank, *JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition*. *JAKSTAT*, 2013. **2**(4): p. e24635.
206. Carracedo, A., et al., *Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer*. *J Clin Invest*, 2008. **118**(9): p. 3065-74.
207. Garrett, J.T., et al., *Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase*. *Proc Natl Acad Sci U S A*, 2011. **108**(12): p. 5021-6.
208. Guo, S. and G.E. Sonenshein, *Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway*. *Mol Cell Biol*, 2004. **24**(19): p. 8681-90.
209. Will, M., et al., *Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling*. *Cancer Discov*, 2014. **4**(3): p. 334-47.
210. Chandarlapaty, S., et al., *AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity*. *Cancer Cell*, 2011. **19**(1): p. 58-71.
211. Wallin, J.J., et al., *GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway*. *Mol Cancer Ther*, 2011. **10**(12): p. 2426-36.
212. Spoerke, J.M., et al., *Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models*. *Clin Cancer Res*, 2012. **18**(24): p. 6771-83.
213. Falchook, G.S., et al., *Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial*. *Lancet*, 2012. **379**(9829): p. 1893-901.
214. Dienstmann, R., et al., *Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors*. *Mol Cancer Ther*, 2014. **13**(5): p. 1021-31.
215. Fritsch, C., et al., *Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials*. *Mol Cancer Ther*, 2014. **13**(5): p. 1117-29.
216. Furet, P., et al., *Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation*. *Bioorg Med Chem Lett*, 2013. **23**(13): p. 3741-8.
217. Fritsch, C., Schnall C, Chatenay-Rivauday C, Guthy DA, Poaver AD, Caravatti G, *NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent*. *Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research*; Chicago IL, 2012. **Abstract 3748**.
218. Dejan Juric , J.R., Ana M. Gonzalez-Angulo, Howard A. Burris, Johanna Bendell, Jordan D. Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, and Jose Baselga, *BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy*

- results from the first-in-human study Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012. **73**(LB-64).
219. Rivero, R.A., Hardwicke MA, *Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta for the treatment of PTEN deficient tumors.* Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; Chicago IL, 2012. **Abstract 2913**
 220. Ni, J., et al., *Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent.* Cancer Discov, 2012. **2**(5): p. 425-33.
 221. Certal, V., et al., *Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.* J Med Chem, 2014. **57**(3): p. 903-20.
 222. Vanhaesebroeck, B., et al., *P110delta, a novel phosphoinositide 3-kinase in leukocytes.* Proc Natl Acad Sci U S A, 1997. **94**(9): p. 4330-5.
 223. Pao, W. and V.A. Miller, *Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.* J Clin Oncol, 2005. **23**(11): p. 2556-68.
 224. Karakas, B., K.E. Bachman, and B.H. Park, *Mutation of the PIK3CA oncogene in human cancers.* Br J Cancer, 2006. **94**(4): p. 455-9.
 225. Roberts, P.J., et al., *Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?* J Clin Oncol, 2010. **28**(31): p. 4769-77.
 226. LoPiccolo, J., et al., *Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.* Drug Resist Updat, 2008. **11**(1-2): p. 32-50.
 227. Shaw, R.J. and L.C. Cantley, *Ras, PI(3)K and mTOR signalling controls tumour cell growth.* Nature, 2006. **441**(7092): p. 424-30.
 228. Gustafson, A.M., et al., *Airway PI3K pathway activation is an early and reversible event in lung cancer development.* Sci Transl Med, 2010. **2**(26): p. 26ra25.
 229. Liu, P., et al., *Targeting the phosphoinositide 3-kinase pathway in cancer.* Nat Rev Drug Discov, 2009. **8**(8): p. 627-44.
 230. Jia, S., T.M. Roberts, and J.J. Zhao, *Should individual PI3 kinase isoforms be targeted in cancer?* Curr Opin Cell Biol, 2009. **21**(2): p. 199-208.
 231. Vanhaesebroeck, B., et al., *The emerging mechanisms of isoform-specific PI3K signalling.* Nat Rev Mol Cell Biol, 2010. **11**(5): p. 329-41.
 232. Zhao, J.J., et al., *The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.* Proc Natl Acad Sci U S A, 2006. **103**(44): p. 16296-300.
 233. Foukas, L.C., et al., *Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.* Nature, 2006. **441**(7091): p. 366-70.
 234. Gupta, S., et al., *Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.* Cell, 2007. **129**(5): p. 957-68.
 235. Puri, K.D. and M.R. Gold, *Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.* Front Immunol, 2012. **3**: p. 256.
 236. Herman, S.E., et al., *Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.* Blood, 2010. **116**(12): p. 2078-88.
 237. Altman, S.A., L. Randers, and G. Rao, *Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations.* Biotechnol Prog, 1993. **9**(6): p. 671-4.

238. O'Brien, J., et al., *Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity*. Eur J Biochem, 2000. **267**(17): p. 5421-6.
239. Balko, J.M., et al., *Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors*. BMC Genomics, 2006. **7**: p. 289.
240. Jamieson, S., et al., *A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types*. Biochem J, 2011. **438**(1): p. 53-62.
241. Jackson, S.P., et al., *PI 3-kinase p110beta: a new target for antithrombotic therapy*. Nat Med, 2005. **11**(5): p. 507-14.
242. Lannutti, B.J., et al., *CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability*. Blood, 2011. **117**(2): p. 591-4.
243. Ikeda, H., et al., *PI3K/p110{delta} is a novel therapeutic target in multiple myeloma*. Blood, 2010. **116**(9): p. 1460-8.
244. Yaguchi, S., et al., *Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor*. J Natl Cancer Inst, 2006. **98**(8): p. 545-56.
245. Zardavas, D., J. Baselga, and M. Piccart, *Emerging targeted agents in metastatic breast cancer*. Nat Rev Clin Oncol, 2013. **10**(4): p. 191-210.
246. Alan Huang, C.F., Christopher Wilson, Anupama Reddy, Manway Liu, Joseph Lehar, Cornelia Quadt, Francesco Hofmann, and Robert Schlegel, *in vivo activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel* Cancer Res, 2012. **72**(3749).
247. *Comprehensive genomic characterization of squamous cell lung cancers*. Nature, 2012. **489**(7417): p. 519-25.
248. Paez, J.G., et al., *EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy*. Science, 2004. **304**(5676): p. 1497-500.
249. Lynch, T.J., et al., *Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib*. N Engl J Med, 2004. **350**(21): p. 2129-39.
250. Soda, M., et al., *Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer*. Nature, 2007. **448**(7153): p. 561-6.
251. Hammerman, P.S., P.A. Janne, and B.E. Johnson, *Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer*. Clin Cancer Res, 2009. **15**(24): p. 7502-7509.
252. Courtney, K.D., R.B. Corcoran, and J.A. Engelman, *The PI3K pathway as drug target in human cancer*. J Clin Oncol, 2010. **28**(6): p. 1075-83.
253. Maira, S.M., et al., *PI3K inhibitors for cancer treatment: where do we stand?* Biochem Soc Trans, 2009. **37**(Pt 1): p. 265-72.
254. Hu, L., et al., *In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)*. Clin Cancer Res, 2000. **6**(3): p. 880-6.
255. Edgar, K.A., et al., *Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors*. Cancer Res, 2010. **70**(3): p. 1164-72.
256. Marques, M., et al., *Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase*. Mol Cell Biol, 2008. **28**(8): p. 2803-14.
257. Marques, M., et al., *Specific function of phosphoinositide 3-kinase beta in the control of DNA replication*. Proc Natl Acad Sci U S A, 2009. **106**(18): p. 7525-30.

258. Berenjano, I.M., et al., *Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor*. *Biochem J*, 2012. **442**(1): p. 151-9.
259. Silio, V., J. Redondo-Munoz, and A.C. Carrera, *Phosphoinositide 3-kinase beta regulates chromosome segregation in mitosis*. *Mol Biol Cell*, 2012.
260. Utermark, T., et al., *The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis*. *Genes Dev*, 2012. **26**(14): p. 1573-86.
261. Herman, S.E., et al., *The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia*. *Blood*, 2011. **117**(16): p. 4323-7.
262. Fruman, D.A. and C. Rommel, *PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic*. *Cancer Discov*, 2011. **1**(7): p. 562-72.
263. Chakrabarty, A., et al., *Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors*. *Proc Natl Acad Sci U S A*, 2012. **109**(8): p. 2718-23.
264. Chen, C.D., et al., *Molecular determinants of resistance to antiandrogen therapy*. *Nat Med*, 2004. **10**(1): p. 33-9.
265. Musgrove, E.A. and R.L. Sutherland, *Biological determinants of endocrine resistance in breast cancer*. *Nat Rev Cancer*, 2009. **9**(9): p. 631-43.
266. Shepherd, F.A., et al., *Erlotinib in previously treated non-small-cell lung cancer*. *N Engl J Med*, 2005. **353**(2): p. 123-32.
267. Hidalgo, M., et al., *Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies*. *J Clin Oncol*, 2001. **19**(13): p. 3267-79.
268. Hensing, T.A., et al., *Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer*. *Lung Cancer*, 2005. **47**(2): p. 253-9.
269. Landi, L.C.F., *TKIs as maintenance therapy in NSCLC: finding the old in the new INFORMATION*. *Transl Lung Cancer Res* 2012. **1**(2): p. 160-162.
270. Janne, P.A., *Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours*. *Lung Cancer*, 2008. **60 Suppl 2**: p. S3-9.
271. Han, S.W., et al., *Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation*. *Clin Cancer Res*, 2006. **12**(8): p. 2538-44.
272. Bedard, P.L., et al., *Tumour heterogeneity in the clinic*. *Nature*, 2013. **501**(7467): p. 355-64.
273. Cappuzzo, F., et al., *Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study*. *Lancet Oncol*, 2010. **11**(6): p. 521-9.
274. Roberts, P.J. and T.E. Stinchcombe, *KRAS mutation: should we test for it, and does it matter?* *J Clin Oncol*, 2013. **31**(8): p. 1112-21.
275. Neal, J.W., *The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer*. *Future Oncol*, 2010. **6**(12): p. 1827-32.
276. Pao, W., et al., *KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib*. *PLoS Med*, 2005. **2**(1): p. e17.
277. Dieterle, C.P., et al., *Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients*. *Clin Cancer Res*, 2004. **10**(2): p. 641-50.

278. Parsons, B.L., et al., *ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue*. *Cancer Invest*, 2010. **28**(4): p. 364-75.
279. Jang, K.S., et al., *Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma*. *Histopathology*, 2010. **56**(2): p. 229-39.
280. Han, C., et al., *EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis*. *Cancer Invest*, 2011. **29**(9): p. 626-34.
281. Chou, T.C., *Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies*. *Pharmacol Rev*, 2006. **58**(3): p. 621-81.
282. Glickman, M.S. and C.L. Sawyers, *Converting cancer therapies into cures: lessons from infectious diseases*. *Cell*, 2012. **148**(6): p. 1089-98.
283. Haagensen, E.J., et al., *The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition*. *Br J Cancer*, 2012. **106**(8): p. 1386-94.
284. Meng, J., et al., *Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim*. *PLoS One*, 2010. **5**(9): p. e13026.
285. Jokinen, E., N. Laurila, and J.P. Koivunen, *Alternative dosing of dual PI3K and MEK inhibition in cancer therapy*. *BMC Cancer*, 2012. **12**: p. 612.
286. Maira, S.M., et al., *Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor*. *Mol Cancer Ther*, 2012. **11**(2): p. 317-28.
287. O'Brien, C., et al., *Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models*. *Clin Cancer Res*, 2010. **16**(14): p. 3670-83.
288. Bendell, J.C., et al., *Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors*. *J Clin Oncol*, 2012. **30**(3): p. 282-90.
289. Ihle, N.T., et al., *Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance*. *Cancer Res*, 2009. **69**(1): p. 143-50.
290. Mascaux, C., et al., *The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis*. *Br J Cancer*, 2005. **92**(1): p. 131-9.
291. Junttila, T.T., et al., *Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941*. *Cancer Cell*, 2009. **15**(5): p. 429-40.
292. Yao, E., et al., *Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab*. *Clin Cancer Res*, 2009. **15**(12): p. 4147-56.

VITA

Christopher W. Stamatkin

EDUCATION:

B.Sc.: 2000-2005 Biology, Indiana University, Bloomington, IN
Minors: Chemistry, Psychology

RESEARCH EXPERIENCE:

Aug. 2009-Present Ph.D., University of Kentucky, Lexington, KY

Sept. 2006-2009 Research associate, CARI Reproductive Institute,
Chicago, IL

Nov. 2005- Sept. 2006 Research technician, Lead Generation/Lead
Optimization Biology, Eli Lilly & Co. – Advanced
Testing Laboratories, Indianapolis, IN

PROFESSIONAL ORGANIZATIONS:

Associate member, American Association for Cancer Research (AACR)

Associate member, American Society of Reproductive Immunology (AJRI)

Member, Society for the Investigation of Early Pregnancy

PUBLICATIONS:

a. Journal Publications

- 1.) Stamatkin, CW., Westendorf, C., Ratermann, K.L., Lannutti, B. and E.P. Black. Response of NSCLC cells to isoform selective inhibition of PI3K uncovers functional specificities of and compensations by class IA enzymes [Submitted]. *Journal of Pharmacology and Experimental Therapeutics (JPET)*.
- 2.) Ramu S, Stamatkin C, Timms L, Ruble M, Roussev RG, Barnea ER. Preimplantation factor (PIF) detection in maternal circulating in early pregnancy correlates with live birth (bovine model). *Reproductive Biology and Endocrinology*. 2013. Nov 15; 11:105.
- 3.) Roussev RG, Dons'koi BV, Stamatkin C, Ramu S, Chernyshov VP, Coulam CB, Barnea ER. Preimplantation factor inhibits circulating natural killer cell cytotoxicity and reduces CD69 expression: implications for recurrent pregnancy loss therapy. *Reproductive BioMedicine* 2013 Jan; 26(1):79-87.
- 4.) Stamatkin CW, Roussev RG, Stout M, Coulam CB, Triche E, Godke RA, Barnea ER. Preimplantation factor negates embryo toxicity and promotes embryo development in culture. *Reproductive BioMedicine Online*. 2011 Oct;23(4):517-24.
- 5.) Stamatkin CW, Roussev RG, Stout M, Absalon-Medina V, Ramu S, Goodman C, Coulam CB, O'Gilbert R, Godke R, Barnea, ER. Preimplantation factor (PIF) correlates with early mammalian embryo development-bovine and murine models. *Reproductive Biology and Endocrinology*. 2011 May15;9:63.
- 6.) Shaaban KA, Stamatkin C, Damodaron C, Rohr J. 11-Deoxyandomycinone and landomycins X-Z, new cytotoxic angucyclin(on)es from *Streptomyces cyanogenus* K62 mutant strain. *Journal of Antibiotics*. 2011 Jan;64(1):141-50.

b. Abstracts/Presentations

- 1.) Stamatkin CW, Westendorf CL, Biliter R, Black EP. Targeting PI3K isoforms as a novel treatment for NSCLC. *Molecular Therapeutics of Cancer Research conference (CMTRA)*. Boulder, CO (2013).

- 2.) Stamatkin CW, Westendorf CL, Biliter R, Black EP. Targeting PI3K isoforms as a novel treatment for NSCLC. Markey Cancer Center Research Day. University of Kentucky. (2013).
- 3.) Stamatkin CW, Westendorf CL, Biliter R, Black EP. Novel treatment strategies for inhibiting RAS mutant NSCLC. Markey Cancer Center Research Day. University of Kentucky. (2012).
- 4.) ER Barnea, Kirk D, Ramu S, Rivnay B, Sathiyasslan T, Stamatkin C, Roussev R, Paidas MJ Preimplantation Factor (PIF*) orchestrates systemic anti-inflammatory response by immune cells: A direct effect on peripheral blood mononuclear cells (PBMC). Society for Maternal Fetal Medicine. 32st Annual Scientific Meeting. Dallas, TX (2012).
- 5.) Stamatkin CW, Westendorf CL, Ratermann K, Bryant J, Jones B, Milewiska M, Lanutti B, Black EP. CAL-120, an orally available isoform selective PI3K inhibitor for the potential treatment of advanced non-small cell lung cancers (NSCLC). Markey Cancer Center Research Day. University of Kentucky. (2011).
- 6.) Barnea, ER, Barder, TJ, Stamatkin, C, Coulam, CB, Roussev, RG, Absalon-Medina V, Gilbert R, Lubman, DM, Liu Y, Paidas MJ. PreImplantation Factor (PIF*) Directly Targets and Rescues Embryos from Adverse Environment: Relevance for Recurrent Pregnancy Loss (RPL). European Society of Human Reproduction and Embryology. 27th Annual Meeting, Stockholm, (2011).
- 7.) Stamatkin C, Kumar R, Damodaron C. Induction of miR-1290 inhibits Akt-mediated cell proliferation in prostate cancer. AACR 102nd Annual Meeting, Orlando, FL (2011).
- 8.) Stamatkin C, Ko CE, El-Amouri I, Oakley OR. Rapid Recruitment of Novel Subsets of Splenic Monocytes to the Periovarian Ovary. 30th Annual Conference of American Society for Reproductive Immunology. Nemaquin, PA (2010).
- 9.) CW Stamatkin, S Ramu, Sui Qu, RG Roussev, CB Coulam Preimplantation Factor (PIF) Suppresses Natural Killer Cell Cytotoxicity. 29th Annual Conference of American Society for Reproductive Immunology. Orlando, FL. (2009).
- 8.) CW Stamatkin, S Ramu, RG Roussev, CB Coulam. Preimplantation Factor (PIF) binds to mouse embryo. 29th Annual Conference of American Society for Reproductive Immunology. Orlando, FL. (2009).
- 9.) S Ramu, CW Stamatkin, RG Roussev, CB Coulam. Developing Immuno-Polymerase Chain Reaction (IPCR) a Highly Sensitive and Specific Assay for Detecting sHLA-G from Embryo Culture Media.

29th Annual Conference of American Society for Reproductive Immunology. Orlando, FL. (2009).

- 10.) Promponas E¹, Keramitsoglou T², Ramu S. ^{3,5}, Stamatkin CW ^{3,5}
Pantos K ⁶, Koussoulakos S ¹, Varla-Leftherioti M ², and Barnea E
R^{3,4,5} Preimplantation Factor (PIF*) as a biomarker for better embryo
selection in IVF. World Congress on Human Reproduction. Venice,
Italy. (2009).
- 11.) Moschandreou D ¹, Keramitsoglou T ¹, Ramu S^{2,4}, Stamatkin, CW^{2,4},
Varla-Leftherioti M ¹), and Barnea ER ^{2,4}. Circulating Levels of
Preimplantation Factor (PIF*) has Strong Correlation with Favorable
Pregnancy Outcome. World Congress on Human Reproduction.
Venice, Italy (2009).
- 12.) CW Stamatkin, RG Roussev, S Ramu, CB Coulam, ER Barnea.
Preimplantation Factor Promotes Embryo Survival. American Society
for Reproductive Immunology, 59 (2008) 643-517.
- 13.) S Ramu, CW Stamatkin, B Seguin, C Komar, M Ruble, M Barzani, A
Khan, RG Roussev, CB Coulam, ER Barnea. Early Pregnancy
Diagnosis in Cows using PIF-based ELISA. American Society for
Reproductive Immunology, 59 (2008) 643-517.